[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fVoj2mjmXw_PP6rXku4ApB00oMy94CEw8phpew0eRC-Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University of Arizona",[4],463,false,100,11,115863,47,318,[14,17,20,22,24,27,30,33],{"name":15,"count":16},"Breast Cancer",23,{"name":18,"count":19},"Obesity",12,{"name":21,"count":19},"Cancer",{"name":23,"count":9},"Depression",{"name":25,"count":26},"Prostate Cancer",9,{"name":28,"count":29},"Sleep",8,{"name":31,"count":32},"Hypertension",7,{"name":34,"count":32},"Obstructive Sleep Apnea",[36,41,46,51,56,61,66,71,76,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04725617","Wellness Intervention for Smoking and HIV","2025-09-28","Varenicline",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05237960","Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia","2025-11-07","Extended Release Metformin Hydrochloride",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05019456","Exercise and COVID-19 Viral T-cell Immunity","2025-12-25","COVID-19 Vaccine",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04062565","Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH","2025-12-31","Treprostinil Injectable Product",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT03781115","Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia","2026-02-10","Ziprasidone",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04820179","Atezolizumab + Cabozantinib in Patients w\u002F Metastatic, Refractory Pancreatic Cancer","2026-02-20","Cabozantinib + Atezolizumab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05709574","Tadalafil Effect + Chemotherapy in Resectable Gastric\u002FGEJ Cancer","2026-03-30","Tadalafil 20 MG",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05933603","Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome","2026-06","Atomoxetine and Oxybutynin",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT05231460","Pain Management Study","Active Comparator: narcotic regimen with TAP block",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06110065","CT-guided Pudendal Nerve Cryoneurolysis for Palliation of Malignancy-induced Pelvic Pain","2026-11","CT-guided Pudendal Nerve Cryoneurolysis",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,123,141,169,194,212,230,248,270,288,326,358,384,410,428,459,477,504,522,557,575,598,626,653,677,699,722,755,777,795,827,845,863,881,907,940,958,976,994,1012,1034,1052,1083,1101,1127,1145,1167,1189,1225,1243,1270,1295,1320,1346,1373,1391,1409,1436,1459,1486,1504,1532,1550,1575,1593,1619,1644,1670,1693,1717,1742,1768,1791,1817,1845,1870,1947,1992,2037,2078,2117,2151,2185,2212,2250,2286,2308,2332,2381,2399,2427,2453,2478,2496,2514,2532,2555,2586,2604,2628,2655,2673,2705,2723,2741,2759,2787,2813,2838,2856,2885,2910,2935,2962,2980,2998,3016,3034,3052,3070,3093,3111,3129,3147,3165,3191,3209,3233,3256,3274,3299,3323,3348,3366,3384,3409,3427,3450,3474,3501,3519,3544,3573,3591,3612,3636,3664,3682,3700,3726,3744,3766,3794,3812,3835,3853,3880,3898,3916,3941,3967,3990,4014,4041,4071,4095,4113,4138,4156,4181,4206,4224,4251,4276,4301,4334,4360,4378,4404,4430,4455,4473,4500,4518,4536,4554,4572,4596,4622,4647,4672,4690,4713,4738,4761,4782,4808,4835,4860,4878,4901],{"intervention":94,"totalTrials":95,"cells":96},"ato-oxy",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":121},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},"NCT07280468","Endotype DIrected Treatment for OSA in Down Syndrome","RECRUITING",[90],"2030-01","2026-03-14",200,[117,118],"Obstructive Sleep Apnea (OSA)","Down Syndrome",[94,120],"Oxygen",{"trials":122,"activeCount":99},[],{"intervention":120,"totalTrials":95,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":139},{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":99},[],{"trials":132,"activeCount":99},[],{"trials":134,"activeCount":95,"soonestReadout":113},[135],{"nctId":109,"briefTitle":110,"status":111,"phases":136,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":137,"interventions":138},[90],[117,118],[94,120],{"trials":140,"activeCount":99},[],{"intervention":142,"totalTrials":95,"cells":143},"Antibiotic loaded calcium sulfate beads",{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":167},{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":99},[],{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":99},[],{"trials":153,"activeCount":95,"soonestReadout":159},[154],{"nctId":155,"briefTitle":156,"status":157,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":8,"conditions":162,"interventions":166},"NCT07072923","Antibiotic Impregnated Beads in Osteomyelitis","NOT_YET_RECRUITING",[90],"2027-07-31","2027-09-30","2025-09-01",[163,164,165],"Osteomyelitis of the Foot","Antibiotic Impregnated Beads","Osteomyelitis of Lower Extremities",[142],{"trials":168,"activeCount":99},[],{"intervention":79,"totalTrials":95,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":192},{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":99},[],{"trials":176,"activeCount":99},[],{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":95,"soonestReadout":74},[181],{"nctId":77,"briefTitle":78,"status":182,"phases":183,"primaryCompletion":74,"completion":74,"start":184,"enrollment":185,"conditions":186,"interventions":188},"ENROLLING_BY_INVITATION",[90],"2022-02-18",244,[187],"Pain, Postoperative",[79,189,190,191],"Active Comparator: narcotic regimen with no TAP block","non-narcotic regimen with TAP block","non-narcotic regimen with no TAP block",{"trials":193,"activeCount":99},[],{"intervention":189,"totalTrials":95,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":210},{"trials":197,"activeCount":99},[],{"trials":199,"activeCount":99},[],{"trials":201,"activeCount":99},[],{"trials":203,"activeCount":99},[],{"trials":205,"activeCount":95,"soonestReadout":74},[206],{"nctId":77,"briefTitle":78,"status":182,"phases":207,"primaryCompletion":74,"completion":74,"start":184,"enrollment":185,"conditions":208,"interventions":209},[90],[187],[79,189,190,191],{"trials":211,"activeCount":99},[],{"intervention":190,"totalTrials":95,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":99},[],{"trials":219,"activeCount":99},[],{"trials":221,"activeCount":99},[],{"trials":223,"activeCount":95,"soonestReadout":74},[224],{"nctId":77,"briefTitle":78,"status":182,"phases":225,"primaryCompletion":74,"completion":74,"start":184,"enrollment":185,"conditions":226,"interventions":227},[90],[187],[79,189,190,191],{"trials":229,"activeCount":99},[],{"intervention":191,"totalTrials":95,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":99},[],{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":99},[],{"trials":241,"activeCount":95,"soonestReadout":74},[242],{"nctId":77,"briefTitle":78,"status":182,"phases":243,"primaryCompletion":74,"completion":74,"start":184,"enrollment":185,"conditions":244,"interventions":245},[90],[187],[79,189,190,191],{"trials":247,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":266,"NA":268},{"trials":251,"activeCount":99},[],{"trials":253,"activeCount":99},[],{"trials":255,"activeCount":99},[],{"trials":257,"activeCount":95,"soonestReadout":54},[258],{"nctId":52,"briefTitle":53,"status":111,"phases":259,"primaryCompletion":54,"completion":54,"start":260,"enrollment":261,"conditions":262,"interventions":264},[89],"2019-03-25",20,[263],"Pulmonary Arterial Hypertension",[55,265],"Riociguat Pill",{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":99},[],{"intervention":265,"totalTrials":95,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":284,"NA":286},{"trials":273,"activeCount":99},[],{"trials":275,"activeCount":99},[],{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":95,"soonestReadout":54},[280],{"nctId":52,"briefTitle":53,"status":111,"phases":281,"primaryCompletion":54,"completion":54,"start":260,"enrollment":261,"conditions":282,"interventions":283},[89],[263],[55,265],{"trials":285,"activeCount":99},[],{"trials":287,"activeCount":99},[],{"intervention":289,"totalTrials":290,"cells":291},"Allopregnanolone",2,{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":307,"PHASE3":320,"PHASE4":322,"NA":324},{"trials":293,"activeCount":99},[],{"trials":295,"activeCount":99},[296],{"nctId":297,"briefTitle":298,"status":299,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT03748303","Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study","TERMINATED",[87],"2022-12-21","2019-10-01",6,[305],"Alzheimer Dementia",[289],{"trials":308,"activeCount":95,"soonestReadout":313},[309],{"nctId":310,"briefTitle":311,"status":111,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":8,"conditions":316,"interventions":319},"NCT04838301","Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease",[88],"2026-11-18","2027-03-18","2023-08-15",[305,317,318],"Late Onset Alzheimer Disease","Neurodegenerative Diseases",[289],{"trials":321,"activeCount":99},[],{"trials":323,"activeCount":99},[],{"trials":325,"activeCount":99},[],{"intervention":75,"totalTrials":290,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":329,"activeCount":99},[],{"trials":331,"activeCount":99},[],{"trials":333,"activeCount":95,"soonestReadout":74},[334,341],{"nctId":72,"briefTitle":73,"status":335,"phases":336,"primaryCompletion":74,"completion":74,"start":337,"enrollment":338,"conditions":339,"interventions":340},"ACTIVE_NOT_RECRUITING",[88],"2023-09-29",36,[34,118],[75],{"nctId":342,"briefTitle":343,"status":344,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":350},"NCT04115878","Medications for Obstructive Sleep Apnea In Children With Down Syndrome","COMPLETED",[88],"2022-12-30","2020-10-21",22,[34,118],[351],"Atomoxetine and oxybutynin",{"trials":353,"activeCount":99},[],{"trials":355,"activeCount":99},[],{"trials":357,"activeCount":99},[],{"intervention":359,"totalTrials":95,"cells":360},"1% plain lidocaine and 0.25% plain bupivacaine",{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":362,"activeCount":99},[],{"trials":364,"activeCount":99},[],{"trials":366,"activeCount":95,"soonestReadout":371},[367],{"nctId":368,"briefTitle":369,"status":182,"phases":370,"primaryCompletion":371,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":377},"NCT04732507","Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome",[88],"2026-12-09","2021-04-20",300,[375,376],"Myofascial Pain","Myofascial Trigger Point Pain",[359],{"trials":379,"activeCount":99},[],{"trials":381,"activeCount":99},[],{"trials":383,"activeCount":99},[],{"intervention":385,"totalTrials":95,"cells":386},"Angiotensin",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":404,"PHASE4":406,"NA":408},{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"trials":392,"activeCount":95,"soonestReadout":397},[393],{"nctId":394,"briefTitle":395,"status":111,"phases":396,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT06282965","Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury",[87,88],"2027-09","2024-05-28",90,[401],"Traumatic Brain Injury",[385,403],"Sterile saline",{"trials":405,"activeCount":99},[],{"trials":407,"activeCount":99},[],{"trials":409,"activeCount":99},[],{"intervention":403,"totalTrials":95,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":422,"PHASE4":424,"NA":426},{"trials":413,"activeCount":99},[],{"trials":415,"activeCount":99},[],{"trials":417,"activeCount":95,"soonestReadout":397},[418],{"nctId":394,"briefTitle":395,"status":111,"phases":419,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":420,"interventions":421},[87,88],[401],[385,403],{"trials":423,"activeCount":99},[],{"trials":425,"activeCount":99},[],{"trials":427,"activeCount":99},[],{"intervention":429,"totalTrials":95,"cells":430},"Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks",{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":95,"soonestReadout":441},[437],{"nctId":438,"briefTitle":439,"status":335,"phases":440,"primaryCompletion":441,"completion":441,"start":442,"enrollment":8,"conditions":443,"interventions":451},"NCT07099222","Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks",[87,88],"2026-12-31","2024-10-10",[444,445,446,447,448,449,450],"Postoperative Pain","Nausea and Vomiting, Postoperative","Dizziness","Constipation","Duration of Response","Narcotics Consumption","Pain After Surgery",[429,452],"Ropivacaine with low, non weight based Dexamethasone additive",{"trials":454,"activeCount":99},[],{"trials":456,"activeCount":99},[],{"trials":458,"activeCount":99},[],{"intervention":452,"totalTrials":95,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":99},[],{"trials":466,"activeCount":95,"soonestReadout":441},[467],{"nctId":438,"briefTitle":439,"status":335,"phases":468,"primaryCompletion":441,"completion":441,"start":442,"enrollment":8,"conditions":469,"interventions":470},[87,88],[444,445,446,447,448,449,450],[429,452],{"trials":472,"activeCount":99},[],{"trials":474,"activeCount":99},[],{"trials":476,"activeCount":99},[],{"intervention":478,"totalTrials":95,"cells":479},"Calcipotriene",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":481,"activeCount":99},[],{"trials":483,"activeCount":99},[],{"trials":485,"activeCount":95,"soonestReadout":490},[486],{"nctId":487,"briefTitle":488,"status":335,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":496},"NCT05699603","Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients",[88],"2027-02-01","2029-02-01","2024-07-02",56,[495],"Actinic Keratosis",[478,497],"Fluorouracil",{"trials":499,"activeCount":99},[],{"trials":501,"activeCount":99},[],{"trials":503,"activeCount":99},[],{"intervention":497,"totalTrials":95,"cells":505},{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":99},[],{"trials":511,"activeCount":95,"soonestReadout":490},[512],{"nctId":487,"briefTitle":488,"status":335,"phases":513,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":514,"interventions":515},[88],[495],[478,497],{"trials":517,"activeCount":99},[],{"trials":519,"activeCount":99},[],{"trials":521,"activeCount":99},[],{"intervention":523,"totalTrials":95,"cells":524},"NAC",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":551,"PHASE4":553,"NA":555},{"trials":526,"activeCount":99},[],{"trials":528,"activeCount":99},[],{"trials":530,"activeCount":95,"soonestReadout":535},[531],{"nctId":532,"briefTitle":533,"status":157,"phases":534,"primaryCompletion":535,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":549},"NCT07227649","NAC-REPAIR for Post-surgical Pain",[88],"2027-01-15","2027-07-15","2026-01-15",80,[540,541,542,543,544,545,546,547,548],"Carpal Tunnel Surgery","Trigger Finger Disorder","De Quervain Syndrome","Guyon's Canal","Dupuytren Contracture","Morton Neuroma","Tarsal Tunnel Syndrome","Plantar Fasciopathy","Peroneal Nerve Entrapment",[523,550],"NAC 0mg\u002Fday",{"trials":552,"activeCount":99},[],{"trials":554,"activeCount":99},[],{"trials":556,"activeCount":99},[],{"intervention":550,"totalTrials":95,"cells":558},{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":560,"activeCount":99},[],{"trials":562,"activeCount":99},[],{"trials":564,"activeCount":95,"soonestReadout":535},[565],{"nctId":532,"briefTitle":533,"status":157,"phases":566,"primaryCompletion":535,"completion":536,"start":537,"enrollment":538,"conditions":567,"interventions":568},[88],[540,541,542,543,544,545,546,547,548],[523,550],{"trials":570,"activeCount":99},[],{"trials":572,"activeCount":99},[],{"trials":574,"activeCount":99},[],{"intervention":70,"totalTrials":95,"cells":576},{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":592,"PHASE4":594,"NA":596},{"trials":578,"activeCount":99},[],{"trials":580,"activeCount":99},[],{"trials":582,"activeCount":95,"soonestReadout":69},[583],{"nctId":67,"briefTitle":68,"status":111,"phases":584,"primaryCompletion":69,"completion":585,"start":586,"enrollment":587,"conditions":588,"interventions":591},[88],"2026-05-31","2023-04-20",10,[589,590],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[70],{"trials":593,"activeCount":99},[],{"trials":595,"activeCount":99},[],{"trials":597,"activeCount":99},[],{"intervention":599,"totalTrials":95,"cells":600},"Pedmark® STS",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":602,"activeCount":99},[],{"trials":604,"activeCount":99},[],{"trials":606,"activeCount":95,"soonestReadout":611},[607],{"nctId":608,"briefTitle":609,"status":111,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":619},"NCT07407582","Ph. I\u002FII Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)",[87,88],"2028-04-30","2026-07-30",25,[615,616,617,618],"Solid Tumor Malignancies","Testicular Cancer","Head and Neck Cancer","Thoracic Cancer",[599],{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"intervention":627,"totalTrials":95,"cells":628},"4-Aminopyridine",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":630,"activeCount":99},[],{"trials":632,"activeCount":99},[],{"trials":634,"activeCount":95,"soonestReadout":639},[635],{"nctId":636,"briefTitle":637,"status":111,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":646},"NCT06003166","4-AP Peripheral Nerve Crossover Trial",[88],"2027-12-31","2028-07-31","2025-04-21",68,[644,645],"Peripheral Nerve Injury","Crush Injury",[627],{"trials":648,"activeCount":99},[],{"trials":650,"activeCount":99},[],{"trials":652,"activeCount":99},[],{"intervention":654,"totalTrials":95,"cells":655},"gemcitabine + docetaxel",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":99},[],{"trials":661,"activeCount":95,"soonestReadout":666},[662],{"nctId":663,"briefTitle":664,"status":111,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":613,"conditions":668,"interventions":670},"NCT05644041","Intravesical Gem\u002FDoce in Patients With NMIBC",[88],"2027-01-31","2023-03-01",[669],"Urinary Bladder Cancer",[654],{"trials":672,"activeCount":99},[],{"trials":674,"activeCount":99},[],{"trials":676,"activeCount":99},[],{"intervention":65,"totalTrials":95,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":95,"soonestReadout":64},[685],{"nctId":62,"briefTitle":63,"status":335,"phases":686,"primaryCompletion":64,"completion":666,"start":687,"enrollment":688,"conditions":689,"interventions":692},[88],"2021-10-12",30,[690,691],"Pancreatic Cancer","Metastatic Pancreatic Cancer",[65],{"trials":694,"activeCount":99},[],{"trials":696,"activeCount":99},[],{"trials":698,"activeCount":99},[],{"intervention":45,"totalTrials":95,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":702,"activeCount":99},[],{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":95,"soonestReadout":44},[707],{"nctId":42,"briefTitle":43,"status":335,"phases":708,"primaryCompletion":44,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":715},[88],"2026-12","2023-01-12",34,[713,714],"Erythroplakia","Oral Leukoplakia",[45],{"trials":717,"activeCount":99},[],{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[],{"intervention":723,"totalTrials":95,"cells":724},"Tarlatamab",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":749,"PHASE4":751,"NA":753},{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":95,"soonestReadout":735},[731],{"nctId":732,"briefTitle":733,"status":111,"phases":734,"primaryCompletion":735,"completion":735,"start":736,"enrollment":688,"conditions":737,"interventions":748},"NCT06814496","Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors",[87,88],"2030-05","2025-09-08",[738,739,740,741,742,616,743,744,745,746,747],"Melanoma","Medullary Thyroid Cancer","Sinonasal Undifferentiated Carcinoma","Esthesioneuroblastoma","Bladder Cancer","Glioblastoma Multiforme","Cervical Cancer","Large Cell Neuroendocrine Carcinoma of the Lung","Non Small Cell Lung Cancer","Merkel Cell Carcinoma",[723],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":769,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":758,"activeCount":99},[],{"trials":760,"activeCount":95,"soonestReadout":59},[761],{"nctId":57,"briefTitle":58,"status":111,"phases":762,"primaryCompletion":59,"completion":59,"start":763,"enrollment":764,"conditions":765,"interventions":767},[87],"2017-11-20",24,[766],"Schizophrenia",[60,768],"Olanzapine",{"trials":770,"activeCount":99},[],{"trials":772,"activeCount":99},[],{"trials":774,"activeCount":99},[],{"trials":776,"activeCount":99},[],{"intervention":768,"totalTrials":95,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":787,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":780,"activeCount":99},[],{"trials":782,"activeCount":95,"soonestReadout":59},[783],{"nctId":57,"briefTitle":58,"status":111,"phases":784,"primaryCompletion":59,"completion":59,"start":763,"enrollment":764,"conditions":785,"interventions":786},[87],[766],[60,768],{"trials":788,"activeCount":99},[],{"trials":790,"activeCount":99},[],{"trials":792,"activeCount":99},[],{"trials":794,"activeCount":99},[],{"intervention":796,"totalTrials":95,"cells":797},"Exercise Mobilized Prophylactic DLI",{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":799,"activeCount":99},[],{"trials":801,"activeCount":95,"soonestReadout":806},[802],{"nctId":803,"briefTitle":804,"status":157,"phases":805,"primaryCompletion":806,"completion":806,"start":585,"enrollment":807,"conditions":808,"interventions":815},"NCT07254793","Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT",[87],"2030-06-01",94,[809,810,811,812,813,814],"Acute Lymphoid Leukemia","Acute Myeloid Leukemia","Acute Undifferentiated Leukemia (AUL)","Myelodysplastic Syndrome","Chronic Myeloid Leukemia","Non-Hodgkin Lymphoma",[796,816,817,818],"Standard Prophylactic DLI","Exercise Mobilized Therapeutic DLI","Standard Therapeutic DLI",{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[],{"intervention":816,"totalTrials":95,"cells":828},{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":830,"activeCount":99},[],{"trials":832,"activeCount":95,"soonestReadout":806},[833],{"nctId":803,"briefTitle":804,"status":157,"phases":834,"primaryCompletion":806,"completion":806,"start":585,"enrollment":807,"conditions":835,"interventions":836},[87],[809,810,811,812,813,814],[796,816,817,818],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":99},[],{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"intervention":817,"totalTrials":95,"cells":846},{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":861},{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":95,"soonestReadout":806},[851],{"nctId":803,"briefTitle":804,"status":157,"phases":852,"primaryCompletion":806,"completion":806,"start":585,"enrollment":807,"conditions":853,"interventions":854},[87],[809,810,811,812,813,814],[796,816,817,818],{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[],{"trials":860,"activeCount":99},[],{"trials":862,"activeCount":99},[],{"intervention":818,"totalTrials":95,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":866,"activeCount":99},[],{"trials":868,"activeCount":95,"soonestReadout":806},[869],{"nctId":803,"briefTitle":804,"status":157,"phases":870,"primaryCompletion":806,"completion":806,"start":585,"enrollment":807,"conditions":871,"interventions":872},[87],[809,810,811,812,813,814],[796,816,817,818],{"trials":874,"activeCount":99},[],{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"intervention":882,"totalTrials":95,"cells":883},"Scopolamine",{"EARLY_PHASE1":884,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":905},{"trials":885,"activeCount":95,"soonestReadout":890},[886],{"nctId":887,"briefTitle":888,"status":182,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":896},"NCT07423923","Representation of Spatiotemporal Information in Human Episodic Memory and Navigation",[86],"2030-03-29","2025-04-01",15,[894,895],"Scopolamine or Placebo","Schema to Organize Memory or no Schema",[882],{"trials":898,"activeCount":99},[],{"trials":900,"activeCount":99},[],{"trials":902,"activeCount":99},[],{"trials":904,"activeCount":99},[],{"trials":906,"activeCount":99},[],{"intervention":908,"totalTrials":95,"cells":909},"Isoproterenol",{"EARLY_PHASE1":910,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":911,"activeCount":95,"soonestReadout":916},[912],{"nctId":913,"briefTitle":914,"status":111,"phases":915,"primaryCompletion":916,"completion":916,"start":917,"enrollment":8,"conditions":918,"interventions":925},"NCT06643221","Exercise as an Immune Adjuvant for Allogeneic Cell Therapies",[86],"2028-12-30","2018-01-24",[919,920,921,922,923,924],"Leukemia","Hematopoetic Stem Cell Transplantation","Donor Lymphocyte Infusion","CAR T-Cell Therapy","Lymphoma","Cell Therapy",[908,926,927,928,929],"Bisoprolol Fumarate Tablet 10 mg","Nadolol","Carvedilol 50 mg","Roflumilast 500 Mcg Oral",{"trials":931,"activeCount":99},[],{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":99},[],{"trials":939,"activeCount":99},[],{"intervention":926,"totalTrials":95,"cells":941},{"EARLY_PHASE1":942,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":943,"activeCount":95,"soonestReadout":916},[944],{"nctId":913,"briefTitle":914,"status":111,"phases":945,"primaryCompletion":916,"completion":916,"start":917,"enrollment":8,"conditions":946,"interventions":947},[86],[919,920,921,922,923,924],[908,926,927,928,929],{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":99},[],{"trials":955,"activeCount":99},[],{"trials":957,"activeCount":99},[],{"intervention":927,"totalTrials":95,"cells":959},{"EARLY_PHASE1":960,"PHASE1":966,"PHASE2":968,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":961,"activeCount":95,"soonestReadout":916},[962],{"nctId":913,"briefTitle":914,"status":111,"phases":963,"primaryCompletion":916,"completion":916,"start":917,"enrollment":8,"conditions":964,"interventions":965},[86],[919,920,921,922,923,924],[908,926,927,928,929],{"trials":967,"activeCount":99},[],{"trials":969,"activeCount":99},[],{"trials":971,"activeCount":99},[],{"trials":973,"activeCount":99},[],{"trials":975,"activeCount":99},[],{"intervention":928,"totalTrials":95,"cells":977},{"EARLY_PHASE1":978,"PHASE1":984,"PHASE2":986,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":979,"activeCount":95,"soonestReadout":916},[980],{"nctId":913,"briefTitle":914,"status":111,"phases":981,"primaryCompletion":916,"completion":916,"start":917,"enrollment":8,"conditions":982,"interventions":983},[86],[919,920,921,922,923,924],[908,926,927,928,929],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":99},[],{"trials":993,"activeCount":99},[],{"intervention":929,"totalTrials":95,"cells":995},{"EARLY_PHASE1":996,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":95,"soonestReadout":916},[998],{"nctId":913,"briefTitle":914,"status":111,"phases":999,"primaryCompletion":916,"completion":916,"start":917,"enrollment":8,"conditions":1000,"interventions":1001},[86],[919,920,921,922,923,924],[908,926,927,928,929],{"trials":1003,"activeCount":99},[],{"trials":1005,"activeCount":99},[],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[],{"intervention":84,"totalTrials":95,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"trials":1023,"activeCount":99},[],{"trials":1025,"activeCount":95,"soonestReadout":83},[1026],{"nctId":81,"briefTitle":82,"status":157,"phases":1027,"primaryCompletion":83,"completion":1028,"start":1029,"enrollment":892,"conditions":1030,"interventions":1032},[],"2027-11","2023-11",[1031],"Malignancy-induced Pelvic Pain",[84,1033],"Percutaneous image-guided cryoneurolysis",{"intervention":1033,"totalTrials":95,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[],{"trials":1043,"activeCount":99},[],{"trials":1045,"activeCount":99},[],{"trials":1047,"activeCount":95,"soonestReadout":83},[1048],{"nctId":81,"briefTitle":82,"status":157,"phases":1049,"primaryCompletion":83,"completion":1028,"start":1029,"enrollment":892,"conditions":1050,"interventions":1051},[],[1031],[84,1033],{"intervention":1053,"totalTrials":95,"cells":1054},"DHEA ovals",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":99},[],{"trials":1066,"activeCount":95,"soonestReadout":1071},[1067],{"nctId":1068,"briefTitle":1069,"status":157,"phases":1070,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1081},"NCT07574216","VEDA Study (DHEA vs Estradiol)",[91],"2031-12-31","2026-06-01",324,[1075,1076,1077,1078,1079,1080],"Post-menopause","Pre-menopause","Sexual Function","Menopause","Vaginal Dryness","Painful Intercourse",[1053,1082],"Estradiol 0.01% Vag Cream",{"intervention":1082,"totalTrials":95,"cells":1084},{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":99},[],{"trials":1090,"activeCount":99},[],{"trials":1092,"activeCount":99},[],{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":95,"soonestReadout":1071},[1097],{"nctId":1068,"briefTitle":1069,"status":157,"phases":1098,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1099,"interventions":1100},[91],[1075,1076,1077,1078,1079,1080],[1053,1082],{"intervention":1102,"totalTrials":95,"cells":1103},"tDCS + language therapy",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[],{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[],{"trials":1113,"activeCount":99},[],{"trials":1115,"activeCount":95,"soonestReadout":1120},[1116],{"nctId":1117,"briefTitle":1118,"status":111,"phases":1119,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":261,"conditions":1123,"interventions":1125},"NCT04920318","Enhancing Language Function in Primary Progressive Aphasia",[91],"2026-12-30","2027-06-15","2021-08-30",[1124],"Primary Progressive Aphasia",[1102,1126],"sham TDCS + language therapy",{"intervention":1126,"totalTrials":95,"cells":1128},{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1130,"activeCount":99},[],{"trials":1132,"activeCount":99},[],{"trials":1134,"activeCount":99},[],{"trials":1136,"activeCount":99},[],{"trials":1138,"activeCount":99},[],{"trials":1140,"activeCount":95,"soonestReadout":1120},[1141],{"nctId":1117,"briefTitle":1118,"status":111,"phases":1142,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":261,"conditions":1143,"interventions":1144},[91],[1124],[1102,1126],{"intervention":50,"totalTrials":95,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1148,"activeCount":99},[],{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":99},[],{"trials":1154,"activeCount":99},[],{"trials":1156,"activeCount":99},[],{"trials":1158,"activeCount":95,"soonestReadout":49},[1159],{"nctId":47,"briefTitle":48,"status":335,"phases":1160,"primaryCompletion":49,"completion":49,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1166},[91],"2021-03-09",26,[1164,1165],"COVID-19 Respiratory Infection","Influenza",[50],{"intervention":40,"totalTrials":95,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":99},[],{"trials":1174,"activeCount":99},[],{"trials":1176,"activeCount":99},[],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":95,"soonestReadout":39},[1181],{"nctId":37,"briefTitle":38,"status":111,"phases":1182,"primaryCompletion":39,"completion":39,"start":1183,"enrollment":115,"conditions":1184,"interventions":1188},[91],"2021-11-16",[1185,28,1186,1187],"HIV","Smoking Cessation","Cardiovascular Diseases",[40],{"intervention":1190,"totalTrials":290,"cells":1191},"Dexmedetomidine",{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1198,"PHASE4":1200,"NA":1223},{"trials":1193,"activeCount":99},[],{"trials":1195,"activeCount":99},[],{"trials":1197,"activeCount":99},[],{"trials":1199,"activeCount":99},[],{"trials":1201,"activeCount":99},[1202,1212],{"nctId":1203,"briefTitle":1204,"status":344,"phases":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1211},"NCT00405847","A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients",[90],"2007-05","2006-07",17,[28,1210],"Critical Illness",[1190],{"nctId":1213,"briefTitle":1214,"status":344,"phases":1215,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":399,"conditions":1218,"interventions":1221},"NCT01050699","Sleep Intervention During Acute Lung Injury",[90],"2019-01","2009-08",[1210,28,1219,1220],"Acute Lung Injury","Acute Respiratory Distress Syndrome",[1190,1222],"Midazolam and Fentanyl",{"trials":1224,"activeCount":99},[],{"intervention":1222,"totalTrials":95,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1235,"NA":1241},{"trials":1228,"activeCount":99},[],{"trials":1230,"activeCount":99},[],{"trials":1232,"activeCount":99},[],{"trials":1234,"activeCount":99},[],{"trials":1236,"activeCount":99},[1237],{"nctId":1213,"briefTitle":1214,"status":344,"phases":1238,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":399,"conditions":1239,"interventions":1240},[90],[1210,28,1219,1220],[1190,1222],{"trials":1242,"activeCount":99},[],{"intervention":1244,"totalTrials":95,"cells":1245},"ED-Dispensing home and school supervision",{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1268},{"trials":1247,"activeCount":99},[],{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":99},[],{"trials":1255,"activeCount":99},[1256],{"nctId":1257,"briefTitle":1258,"status":344,"phases":1259,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1267},"NCT03952286","ED-Initiated School-based Asthma Medication Supervision",[90],"2020-12-30","2021-01-01","2019-08-01",13,[1265,1266],"Asthma","Asthma in Children",[1244],{"trials":1269,"activeCount":99},[],{"intervention":1271,"totalTrials":95,"cells":1272},"Rozerem 8mg",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1293},{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[],{"trials":1280,"activeCount":99},[],{"trials":1282,"activeCount":99},[1283],{"nctId":1284,"briefTitle":1285,"status":1286,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":688,"conditions":1290,"interventions":1292},"NCT01180855","Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia","UNKNOWN",[90],"2010-09","2007-08",[1291],"Insomnia",[1271],{"trials":1294,"activeCount":99},[],{"intervention":1296,"totalTrials":95,"cells":1297},"ATMX",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1318},{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":99},[],{"trials":1303,"activeCount":99},[],{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[1308],{"nctId":1309,"briefTitle":1310,"status":344,"phases":1311,"primaryCompletion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1317},"NCT00517647","Atomoxetine Pilot Study in Preschool Children With ADHD",[90],"2008-03","2004-04",31,[1316],"Attention Deficit Hyperactivity Disorder",[1296],{"trials":1319,"activeCount":99},[],{"intervention":1321,"totalTrials":95,"cells":1322},"Eszopiclone",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1344},{"trials":1324,"activeCount":99},[],{"trials":1326,"activeCount":99},[],{"trials":1328,"activeCount":99},[],{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[1333],{"nctId":1334,"briefTitle":1335,"status":344,"phases":1336,"primaryCompletion":1217,"completion":1337,"start":1338,"enrollment":1339,"conditions":1340,"interventions":1343},"NCT00822679","Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome",[90],"2010-01","2007-10",5,[1341,1342],"Acute Coronary Syndrome","Sleep Disorder",[1321],{"trials":1345,"activeCount":99},[],{"intervention":1347,"totalTrials":95,"cells":1348},"Standard dose (once daily) PPI plus low-dose antidepressant",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1371},{"trials":1350,"activeCount":99},[],{"trials":1352,"activeCount":99},[],{"trials":1354,"activeCount":99},[],{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[1359],{"nctId":1360,"briefTitle":1361,"status":344,"phases":1362,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1368},"NCT00251732","Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)",[90],"2010-05","2005-03",150,[1367],"Gastroesophageal Reflux Disease",[1347,1369,1370],"Double dose PPI plus evening placebo","Rabeprazole , placebo, placebo",{"trials":1372,"activeCount":99},[],{"intervention":1369,"totalTrials":95,"cells":1374},{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1383,"NA":1389},{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[],{"trials":1382,"activeCount":99},[],{"trials":1384,"activeCount":99},[1385],{"nctId":1360,"briefTitle":1361,"status":344,"phases":1386,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1387,"interventions":1388},[90],[1367],[1347,1369,1370],{"trials":1390,"activeCount":99},[],{"intervention":1370,"totalTrials":95,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1401,"NA":1407},{"trials":1394,"activeCount":99},[],{"trials":1396,"activeCount":99},[],{"trials":1398,"activeCount":99},[],{"trials":1400,"activeCount":99},[],{"trials":1402,"activeCount":99},[1403],{"nctId":1360,"briefTitle":1361,"status":344,"phases":1404,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1405,"interventions":1406},[90],[1367],[1347,1369,1370],{"trials":1408,"activeCount":99},[],{"intervention":1410,"totalTrials":95,"cells":1411},"Gebauers Ethyl Chloride 100% Topical Spray",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1434},{"trials":1413,"activeCount":99},[],{"trials":1415,"activeCount":99},[],{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":99},[],{"trials":1421,"activeCount":99},[1422],{"nctId":1423,"briefTitle":1424,"status":1286,"phases":1425,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1433},"NCT05405452","Vibratory Anesthesia in Trigger Finger Injections",[90],"2025-08-01","2023-08-14",1000,[1430,1431,1432],"Trigger Finger","Pain","Anesthesia, Local",[1410],{"trials":1435,"activeCount":99},[],{"intervention":1437,"totalTrials":95,"cells":1438},"Methylphenidate",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1457},{"trials":1440,"activeCount":99},[],{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[],{"trials":1448,"activeCount":99},[1449],{"nctId":1450,"briefTitle":1451,"status":344,"phases":1452,"primaryCompletion":1312,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1456},"NCT00517504","Methylphenidate Study in Young Children With Developmental Disorders",[90],"2001-05",48,[1316],[1437],{"trials":1458,"activeCount":99},[],{"intervention":1460,"totalTrials":95,"cells":1461},"Belatacept",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1468,"PHASE4":1470,"NA":1484},{"trials":1463,"activeCount":99},[],{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[],{"trials":1471,"activeCount":99},[1472],{"nctId":1473,"briefTitle":1474,"status":1286,"phases":1475,"primaryCompletion":1476,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1482},"NCT01875224","Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression",[90],"2016-08","2013-08",32,[1480,1481],"New Onset Diabetes After Transplant","Kidney Transplantation",[1460,1483],"Tacrolimus",{"trials":1485,"activeCount":99},[],{"intervention":1483,"totalTrials":95,"cells":1487},{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1502},{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":99},[1498],{"nctId":1473,"briefTitle":1474,"status":1286,"phases":1499,"primaryCompletion":1476,"completion":1476,"start":1477,"enrollment":1478,"conditions":1500,"interventions":1501},[90],[1480,1481],[1460,1483],{"trials":1503,"activeCount":99},[],{"intervention":1505,"totalTrials":95,"cells":1506},"Infants in the study group",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1515,"NA":1530},{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[1517],{"nctId":1518,"briefTitle":1519,"status":1286,"phases":1520,"primaryCompletion":1521,"completion":1522,"start":1523,"enrollment":613,"conditions":1524,"interventions":1528},"NCT05364385","Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease",[90],"2023-02","2024-12","2019-12-02",[1525,1219,1526,1527],"Infant, Extremely Premature","Chronic Lung Disease of Prematurity","Budesonide",[1505,1529],"Infants in the control group",{"trials":1531,"activeCount":99},[],{"intervention":1529,"totalTrials":95,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1548},{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[],{"trials":1543,"activeCount":99},[1544],{"nctId":1518,"briefTitle":1519,"status":1286,"phases":1545,"primaryCompletion":1521,"completion":1522,"start":1523,"enrollment":613,"conditions":1546,"interventions":1547},[90],[1525,1219,1526,1527],[1505,1529],{"trials":1549,"activeCount":99},[],{"intervention":1551,"totalTrials":95,"cells":1552},"Topical Steroid Ointment",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1573},{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":99},[],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[1563],{"nctId":1564,"briefTitle":1565,"status":344,"phases":1566,"primaryCompletion":1567,"completion":1567,"start":1568,"enrollment":688,"conditions":1569,"interventions":1571},"NCT03279328","Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents",[90],"2018-07-31","2017-10-10",[1570],"Actinic Keratoses",[1551,1572],"Skin Barrier Moisturier",{"trials":1574,"activeCount":99},[],{"intervention":1572,"totalTrials":95,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1585,"NA":1591},{"trials":1578,"activeCount":99},[],{"trials":1580,"activeCount":99},[],{"trials":1582,"activeCount":99},[],{"trials":1584,"activeCount":99},[],{"trials":1586,"activeCount":99},[1587],{"nctId":1564,"briefTitle":1565,"status":344,"phases":1588,"primaryCompletion":1567,"completion":1567,"start":1568,"enrollment":688,"conditions":1589,"interventions":1590},[90],[1570],[1551,1572],{"trials":1592,"activeCount":99},[],{"intervention":1594,"totalTrials":95,"cells":1595},"sildenafil",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1602,"PHASE4":1604,"NA":1617},{"trials":1597,"activeCount":99},[],{"trials":1599,"activeCount":99},[],{"trials":1601,"activeCount":99},[],{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[1606],{"nctId":1607,"briefTitle":1608,"status":344,"phases":1609,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":26,"conditions":1613,"interventions":1616},"NCT01800292","Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.",[90],"2013-12","2014-12","2013-02",[1614,1615],"Hypertension, Pulmonary Artery","Ventricular Dysfunction, Left",[1594],{"trials":1618,"activeCount":99},[],{"intervention":1620,"totalTrials":95,"cells":1621},"Perampanel Oral",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1642},{"trials":1623,"activeCount":99},[],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"trials":1631,"activeCount":99},[1632],{"nctId":1633,"briefTitle":1634,"status":344,"phases":1635,"primaryCompletion":1636,"completion":1637,"start":1638,"enrollment":261,"conditions":1639,"interventions":1641},"NCT03457129","Fycompa Titration Intervals and Effects on Retention Rate",[90],"2021-02-24","2021-12-15","2018-04-18",[1640],"Epilepsy",[1620],{"trials":1643,"activeCount":99},[],{"intervention":1645,"totalTrials":95,"cells":1646},"Oxytocin",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1668},{"trials":1648,"activeCount":99},[],{"trials":1650,"activeCount":99},[],{"trials":1652,"activeCount":99},[],{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[1657],{"nctId":1658,"briefTitle":1659,"status":344,"phases":1660,"primaryCompletion":1661,"completion":1662,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1667},"NCT03140488","Oxytocin Dosage to Decrease Induction Duration",[90],"2018-10-12","2019-09-05","2017-06-05",140,[18,1666,1645],"Labor, Induced",[1645],{"trials":1669,"activeCount":99},[],{"intervention":1671,"totalTrials":95,"cells":1672},"atomoxetine",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1691},{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":99},[1683],{"nctId":1684,"briefTitle":1685,"status":344,"phases":1686,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1339,"conditions":1689,"interventions":1690},"NCT00856063","Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD)",[90],"2009-12","2009-03",[1316],[1671],{"trials":1692,"activeCount":99},[],{"intervention":1694,"totalTrials":95,"cells":1695},"Duloxetine",{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1704,"NA":1715},{"trials":1697,"activeCount":99},[],{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[],{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[1706],{"nctId":1707,"briefTitle":1708,"status":344,"phases":1709,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":32,"conditions":1712,"interventions":1714},"NCT00517985","Duloxetine for Perimenopausal Depression",[90],"2008-06","2007-02",[1713],"Major Depressive Disorder",[1694],{"trials":1716,"activeCount":99},[],{"intervention":1718,"totalTrials":95,"cells":1719},"Supervised asthma therapy in schools",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1740},{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[1730],{"nctId":1731,"briefTitle":1732,"status":344,"phases":1733,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":1736,"conditions":1737,"interventions":1739},"NCT01997463","Supervised Asthma Medication in Schools (SAMS)",[90],"2016-06","2014-08",442,[1738],"Childhood Asthma",[1718],{"trials":1741,"activeCount":99},[],{"intervention":1743,"totalTrials":95,"cells":1744},"Azithromycin",{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1751,"PHASE4":1764,"NA":1766},{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[1753],{"nctId":1754,"briefTitle":1755,"status":299,"phases":1756,"primaryCompletion":1757,"completion":1758,"start":1759,"enrollment":1760,"conditions":1761,"interventions":1763},"NCT04669288","AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department",[89],"2024-12-10","2025-01-08","2021-09-22",840,[1265,1762],"Wheezing",[1743],{"trials":1765,"activeCount":99},[],{"trials":1767,"activeCount":99},[],{"intervention":1769,"totalTrials":95,"cells":1770},"bupropion SR",{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1777,"PHASE4":1787,"NA":1789},{"trials":1772,"activeCount":99},[],{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[1779],{"nctId":1780,"briefTitle":1781,"status":344,"phases":1782,"completion":1783,"conditions":1784,"interventions":1786},"NCT00344695","Bupropion Treatment for Youth Smoking Cessation",[89],"2003-04",[1785],"Nicotine Dependence",[1769],{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[],{"intervention":1792,"totalTrials":95,"cells":1793},"Ferumoxytol",{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1813,"NA":1815},{"trials":1795,"activeCount":99},[],{"trials":1797,"activeCount":99},[],{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[1802],{"nctId":1803,"briefTitle":1804,"status":344,"phases":1805,"primaryCompletion":1806,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1812},"NCT03657433","Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy",[89],"2021-08-27","2022-04-01","2018-12-17",124,[1811],"Iron Deficiency Anemia of Pregnancy",[1792],{"trials":1814,"activeCount":99},[],{"trials":1816,"activeCount":99},[],{"intervention":1818,"totalTrials":95,"cells":1819},"Selenium",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1826,"PHASE4":1841,"NA":1843},{"trials":1821,"activeCount":99},[],{"trials":1823,"activeCount":99},[],{"trials":1825,"activeCount":99},[],{"trials":1827,"activeCount":99},[1828],{"nctId":1829,"briefTitle":1830,"status":299,"phases":1831,"primaryCompletion":1832,"completion":1833,"start":1834,"enrollment":1835,"conditions":1836,"interventions":1840},"NCT00078897","Selenium for Prevention of Adenomatous Colorectal Polyps",[89],"2014-01-07","2018-05-17","2005-01-20",1621,[1837,1838,1839],"Colorectal Cancer","Adenomatous Colorectal Polyps","Precancerous Condition",[1818],{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"intervention":1846,"totalTrials":95,"cells":1847},"Snake (Micrurus) North American immune F(ab')2 Equine",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1854,"PHASE4":1866,"NA":1868},{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[1856],{"nctId":1857,"briefTitle":1858,"status":344,"phases":1859,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1162,"conditions":1862,"interventions":1865},"NCT01337245","Emergency Treatment of Coral Snake Envenomation With Antivenom",[89],"2016-11-11","2012-05",[1863,1864],"Coral Snake Bite","Toxic Effect of Coral Snake Venom",[1846],{"trials":1867,"activeCount":99},[],{"trials":1869,"activeCount":99},[],{"intervention":1871,"totalTrials":1872,"cells":1873},"rituximab",4,{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":99},[],{"trials":1879,"activeCount":99},[1880,1894,1907,1926],{"nctId":1881,"briefTitle":1882,"status":344,"phases":1883,"primaryCompletion":1884,"completion":1885,"start":1886,"enrollment":764,"conditions":1887,"interventions":1891},"NCT00980395","Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma",[88],"2014-09-12","2018-08-14","2009-07-07",[923,1888,1889,1890],"Mantle Cell Lymphoma","Indolent Lymphoma","SLL",[1871,1892,1893],"bortezomib","cladribine",{"nctId":1895,"briefTitle":1896,"status":344,"phases":1897,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":1339,"conditions":1901,"interventions":1905},"NCT01686165","Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W\u002FRelapsed Aggressive B-Cell NHL",[88],"2016-02-09","2017-11-09","2012-08-31",[1902,1903,1904],"Anaplastic Large Cell Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Mantle Cell Lymphoma",[1906,1871],"belinostat",{"nctId":1908,"briefTitle":1909,"status":1910,"phases":1911,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":99,"conditions":1914,"interventions":1922},"NCT02623920","Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","WITHDRAWN",[88],"2017-05-17","2015-12-16",[1915,1916,1917,1918,1919,1920,1921],"Diffuse Large B Cell Lymphoma","Mediastinal Large B-cell Lymphoma","Grey Zone Lymphoma","High Grade B Cell Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Small Lymphocytic Lymphoma",[1923,1924,1925],"Brentuximab","Bendamustine","Rituximab",{"nctId":1927,"briefTitle":1928,"status":344,"phases":1929,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1934},"NCT00732498","Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W\u002FRelapsed Stage II, III, or IV Follicular NHL",[88],"2018-10-15","2006-05-15",28,[923],[1935,1936,1937,1938,1925,1939,1940],"Methylprednisolone","Etoposide","Cytarabine","Cisplatin","In-Zevalin","Y-Zevalin",{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"intervention":1948,"totalTrials":1949,"cells":1950},"cisplatin",3,{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1980,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[1955,1969],{"nctId":1956,"briefTitle":1957,"status":344,"phases":1958,"primaryCompletion":1959,"completion":1960,"start":1961,"enrollment":892,"conditions":1962,"interventions":1966},"NCT00702299","Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer",[87],"2012-01","2012-10","2007-09",[1963,1964,1965],"Fallopian Tube Cancer","Ovarian Cancer","Peritoneal Cavity Cancer",[1948,1967,1968],"paclitaxel","pemetrexed disodium",{"nctId":1970,"briefTitle":1971,"status":344,"phases":1972,"primaryCompletion":1973,"completion":1974,"start":1975,"enrollment":587,"conditions":1976,"interventions":1978},"NCT00701857","Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer",[87],"2014-04","2015-09","2008-02",[1977],"Esophageal Cancer",[1948,1979],"Pemetrexed",{"trials":1981,"activeCount":99},[1982],{"nctId":1927,"briefTitle":1928,"status":344,"phases":1983,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":1984,"interventions":1985},[88],[923],[1935,1936,1937,1938,1925,1939,1940],{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[],{"intervention":1993,"totalTrials":1949,"cells":1994},"amifostine trihydrate",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[2001,2011,2022],{"nctId":2002,"briefTitle":2003,"status":344,"phases":2004,"completion":2005,"start":2006,"enrollment":1162,"conditions":2007,"interventions":2009},"NCT00003415","Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome",[87,88],"2002-11","1998-09",[919,2008],"Myelodysplastic Syndromes",[1993,2010],"topotecan hydrochloride",{"nctId":2012,"briefTitle":2013,"status":344,"phases":2014,"completion":2005,"start":2015,"enrollment":688,"conditions":2016,"interventions":2018},"NCT00003068","High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer",[88],"1997-06",[15,2017],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[1993,2019,2020,2021],"cyclophosphamide","mitoxantrone hydrochloride","thiotepa",{"nctId":2023,"briefTitle":2024,"status":344,"phases":2025,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":613,"conditions":2028,"interventions":2030},"NCT00003307","Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer",[88],"2001-06","1998-03",[25,2029],"Radiation Toxicity",[1993],{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":99},[],{"trials":2036,"activeCount":99},[],{"intervention":2038,"totalTrials":1949,"cells":2039},"nikkomycin Z",{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2063,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2041,"activeCount":99},[],{"trials":2043,"activeCount":99},[2044,2055],{"nctId":2045,"briefTitle":2046,"status":299,"phases":2047,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":1339,"conditions":2051,"interventions":2053},"NCT01647256","Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions",[87],"2012-08","2013-06","2012-07",[2052],"Healthy",[2054],"Nikkomycin Z",{"nctId":2056,"briefTitle":2057,"status":344,"phases":2058,"primaryCompletion":2059,"completion":2059,"start":2060,"enrollment":1478,"conditions":2061,"interventions":2062},"NCT00834184","Safety and PK of Nikkomycin Z in Healthy Subjects",[87],"2009-09","2008-10",[2052],[2038],{"trials":2064,"activeCount":99},[2065],{"nctId":2066,"briefTitle":2067,"status":299,"phases":2068,"primaryCompletion":2059,"completion":2059,"start":1961,"enrollment":303,"conditions":2069,"interventions":2071},"NCT00614666","Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment",[87,88],[2070],"Coccidioidomycosis",[2038],{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[],{"intervention":2079,"totalTrials":290,"cells":2080},"bevacizumab",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2082,"activeCount":99},[],{"trials":2084,"activeCount":99},[],{"trials":2086,"activeCount":99},[2087,2097],{"nctId":2088,"briefTitle":2089,"status":344,"phases":2090,"primaryCompletion":1337,"completion":1363,"start":2091,"enrollment":2092,"conditions":2093,"interventions":2095},"NCT00130520","Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer",[88],"2005-06",40,[2094],"Ovarian Neoplasms",[2079,2096],"erlotinib",{"nctId":2098,"briefTitle":2099,"status":1910,"phases":2100,"primaryCompletion":2101,"completion":2102,"start":2103,"enrollment":99,"conditions":2104,"interventions":2107},"NCT02065466","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",[87,88],"2015-02","2015-08","2014-07",[2105,2106],"Metastatic Melanoma","Brain Metastases",[2108,2109,2110],"nab-paclitaxel","Temozolomide","Bevacizumab",{"trials":2112,"activeCount":99},[],{"trials":2114,"activeCount":99},[],{"trials":2116,"activeCount":99},[],{"intervention":2118,"totalTrials":290,"cells":2119},"Angiotensin-",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2121,"activeCount":99},[],{"trials":2123,"activeCount":99},[],{"trials":2125,"activeCount":99},[2126,2136],{"nctId":2127,"briefTitle":2128,"status":2129,"phases":2130,"primaryCompletion":1072,"completion":1072,"start":2131,"enrollment":303,"conditions":2132,"interventions":2135},"NCT03159988","Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients","SUSPENDED",[88],"2016-04",[2133,2134],"Chronic Heart Failure","Cognitive Impairment",[2118],{"nctId":2137,"briefTitle":2138,"status":299,"phases":2139,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":303,"conditions":2142,"interventions":2144},"NCT03252093","Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG",[88],"2022-11-15","2017-07-20",[2143,2134],"Coronary Artery Bypass Surgery",[2118],{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[],{"intervention":2152,"totalTrials":290,"cells":2153},"Vismodegib",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2168,"PHASE3":2179,"PHASE4":2181,"NA":2183},{"trials":2155,"activeCount":99},[],{"trials":2157,"activeCount":99},[2158],{"nctId":2159,"briefTitle":2160,"status":344,"phases":2161,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":1872,"conditions":2165,"interventions":2167},"NCT02639117","Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas",[87],"2016-11-02","2017-11-18","2015-11-30",[2166],"Basal Cell Carcinoma",[2152],{"trials":2169,"activeCount":99},[2170],{"nctId":2171,"briefTitle":2172,"status":299,"phases":2173,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":26,"conditions":2176,"interventions":2178},"NCT02067104","Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention",[88],"2016-12-31","2014-02-17",[2177],"Basal Cell Carcinomas",[2152],{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[],{"trials":2184,"activeCount":99},[],{"intervention":1936,"totalTrials":290,"cells":2186},{"EARLY_PHASE1":2187,"PHASE1":2189,"PHASE2":2191,"PHASE3":2206,"PHASE4":2208,"NA":2210},{"trials":2188,"activeCount":99},[],{"trials":2190,"activeCount":99},[],{"trials":2192,"activeCount":99},[2193,2202],{"nctId":2194,"briefTitle":2195,"status":344,"phases":2196,"primaryCompletion":2197,"completion":2198,"start":1289,"enrollment":1314,"conditions":2199,"interventions":2200},"NCT00693719","Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer",[88],"2012-12","2013-05",[15],[1936,2201],"Irinotecan hydrochloride",{"nctId":1927,"briefTitle":1928,"status":344,"phases":2203,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":2204,"interventions":2205},[88],[923],[1935,1936,1937,1938,1925,1939,1940],{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[],{"intervention":1924,"totalTrials":290,"cells":2213},{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2238,"PHASE3":2244,"PHASE4":2246,"NA":2248},{"trials":2215,"activeCount":99},[],{"trials":2217,"activeCount":99},[2218],{"nctId":2219,"briefTitle":2220,"status":344,"phases":2221,"primaryCompletion":1426,"completion":1426,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2236},"NCT02996773","Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine",[87],"2016-11-29",50,[2225,2226,2008,2227,2228,2229,2230,1920,2231,2232,2233,2234,2235],"Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Chronic Myelogenous Leukemia","Lymphoma,Non-Hodgkin","Lymphoma, Hodgkin","Lymphoma, Follicular","Large Cell Lymphoma","Mantle-Cell Lymphoma","Gray Zone Lymphoma","Burkitt Lymphoma","High Risk Undifferentiated Acute Leukemia",[1924,2237],"Cyclophosphamide",{"trials":2239,"activeCount":99},[2240],{"nctId":1908,"briefTitle":1909,"status":1910,"phases":2241,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":99,"conditions":2242,"interventions":2243},[88],[1915,1916,1917,1918,1919,1920,1921],[1923,1924,1925],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"intervention":2251,"totalTrials":290,"cells":2252},"Placebos",{"EARLY_PHASE1":2253,"PHASE1":2266,"PHASE2":2268,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2254,"activeCount":99},[2255],{"nctId":2256,"briefTitle":2257,"status":344,"phases":2258,"primaryCompletion":2259,"completion":2260,"start":2261,"enrollment":2223,"conditions":2262,"interventions":2264},"NCT03855059","IV Steroids Versus Steroids Included in Block for Orthopedic Lower Limb Surgery",[86],"2020-04-28","2020-06-26","2019-06-05",[2263],"Lower Limb Injury",[2251,2265],"Dexamethasone Sodium Phosphate",{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":99},[2270],{"nctId":2271,"briefTitle":2272,"status":344,"phases":2273,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":32,"conditions":2276,"interventions":2278},"NCT03847311","Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients",[88],"2023-10-09","2021-05-03",[15,2277],"Chronic Pain Due to Malignancy (Finding)",[2279,2251],"Sulfasalazine",{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"intervention":2019,"totalTrials":290,"cells":2287},{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2296,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[2292],{"nctId":2219,"briefTitle":2220,"status":344,"phases":2293,"primaryCompletion":1426,"completion":1426,"start":2222,"enrollment":2223,"conditions":2294,"interventions":2295},[87],[2225,2226,2008,2227,2228,2229,2230,1920,2231,2232,2233,2234,2235],[1924,2237],{"trials":2297,"activeCount":99},[2298],{"nctId":2012,"briefTitle":2013,"status":344,"phases":2299,"completion":2005,"start":2015,"enrollment":688,"conditions":2300,"interventions":2301},[88],[15,2017],[1993,2019,2020,2021],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"intervention":2309,"totalTrials":95,"cells":2310},"Hormone replacement therapy",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2315,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":99},[],{"trials":2316,"activeCount":99},[2317],{"nctId":2318,"briefTitle":2319,"status":344,"phases":2320,"completion":2321,"start":2322,"enrollment":373,"conditions":2323,"interventions":2325},"NCT00000399","Bone Estrogen Strength Training",[88],"2001-01","1995-08",[2324],"Osteoporosis",[2309],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"intervention":2333,"totalTrials":95,"cells":2334},"Cetuximab",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"trials":2340,"activeCount":99},[2341],{"nctId":2342,"briefTitle":2343,"status":344,"phases":2344,"primaryCompletion":2345,"completion":2346,"start":2347,"enrollment":2348,"conditions":2349,"interventions":2373},"NCT03422536","Ficlatuzumab w\u002Fwo Cetuximab in Patients w\u002FCetuximab-Resistant, Recurrent or Metastatic Head\u002FNeck Squamous Cell Carcinoma",[88],"2022-03-29","2022-04-05","2017-12-05",78,[2350,2351,2352,2353,2354,2355,2356,2357,2358,2359,2360,2361,2362,2363,2364,2365,2366,2367,2368,2369,617,2370,2371,2372],"Head and Neck Basaloid Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Squamous Cell Carcinoma of Unknown Primary Origin","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IV Oropharyngeal Squamous Cell Carcinoma","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IVC Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Cancer","HNSCC","Stage IV Lip and Oral Cavity Squamous Cell Carcinoma",[2333,2374],"Ficlatuzumab",{"trials":2376,"activeCount":99},[],{"trials":2378,"activeCount":99},[],{"trials":2380,"activeCount":99},[],{"intervention":2374,"totalTrials":95,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2393,"PHASE4":2395,"NA":2397},{"trials":2384,"activeCount":99},[],{"trials":2386,"activeCount":99},[],{"trials":2388,"activeCount":99},[2389],{"nctId":2342,"briefTitle":2343,"status":344,"phases":2390,"primaryCompletion":2345,"completion":2346,"start":2347,"enrollment":2348,"conditions":2391,"interventions":2392},[88],[2350,2351,2352,2353,2354,2355,2356,2357,2358,2359,2360,2361,2362,2363,2364,2365,2366,2367,2368,2369,617,2370,2371,2372],[2333,2374],{"trials":2394,"activeCount":99},[],{"trials":2396,"activeCount":99},[],{"trials":2398,"activeCount":99},[],{"intervention":2400,"totalTrials":95,"cells":2401},"busulfan, and melphalan, and alemtuzumab",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2421,"PHASE4":2423,"NA":2425},{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":99},[],{"trials":2407,"activeCount":99},[2408],{"nctId":2409,"briefTitle":2410,"status":344,"phases":2411,"primaryCompletion":1973,"completion":2412,"start":2059,"enrollment":2413,"conditions":2414,"interventions":2420},"NCT00997386","Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States",[88],"2016-01",16,[2415,2416,2417,2418,2419],"Hematologic Neoplasms","Multiple Myeloma","Anemia, Aplastic","Hemoglobinuria, Paroxysmal","Myelofibrosis",[2400],{"trials":2422,"activeCount":99},[],{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"intervention":2428,"totalTrials":95,"cells":2429},"Metformin",{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2434,"PHASE3":2447,"PHASE4":2449,"NA":2451},{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[2436],{"nctId":2437,"briefTitle":2438,"status":344,"phases":2439,"primaryCompletion":2440,"completion":2441,"start":2442,"enrollment":2443,"conditions":2444,"interventions":2446},"NCT02028221","Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk",[88],"2018-11-30","2022-06-14","2014-03-07",151,[2445],"Breast Cancer Prevention",[2428],{"trials":2448,"activeCount":99},[],{"trials":2450,"activeCount":99},[],{"trials":2452,"activeCount":99},[],{"intervention":2454,"totalTrials":95,"cells":2455},"eflornithine",{"EARLY_PHASE1":2456,"PHASE1":2458,"PHASE2":2460,"PHASE3":2472,"PHASE4":2474,"NA":2476},{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[2462],{"nctId":2463,"briefTitle":2464,"status":344,"phases":2465,"primaryCompletion":2466,"completion":2466,"start":1453,"conditions":2467,"interventions":2470},"NCT00021294","Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis",[88],"2002-06",[2468,2469],"Non-melanomatous Skin Cancer","Precancerous\u002FNonmalignant Condition",[2454,2471],"triamcinolone",{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":99},[],{"intervention":2471,"totalTrials":95,"cells":2479},{"EARLY_PHASE1":2480,"PHASE1":2482,"PHASE2":2484,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":99},[2486],{"nctId":2463,"briefTitle":2464,"status":344,"phases":2487,"primaryCompletion":2466,"completion":2466,"start":1453,"conditions":2488,"interventions":2489},[88],[2468,2469],[2454,2471],{"trials":2491,"activeCount":99},[],{"trials":2493,"activeCount":99},[],{"trials":2495,"activeCount":99},[],{"intervention":1892,"totalTrials":95,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[2504],{"nctId":1881,"briefTitle":1882,"status":344,"phases":2505,"primaryCompletion":1884,"completion":1885,"start":1886,"enrollment":764,"conditions":2506,"interventions":2507},[88],[923,1888,1889,1890],[1871,1892,1893],{"trials":2509,"activeCount":99},[],{"trials":2511,"activeCount":99},[],{"trials":2513,"activeCount":99},[],{"intervention":1893,"totalTrials":95,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[2522],{"nctId":1881,"briefTitle":1882,"status":344,"phases":2523,"primaryCompletion":1884,"completion":1885,"start":1886,"enrollment":764,"conditions":2524,"interventions":2525},[88],[923,1888,1889,1890],[1871,1892,1893],{"trials":2527,"activeCount":99},[],{"trials":2529,"activeCount":99},[],{"trials":2531,"activeCount":99},[],{"intervention":2533,"totalTrials":95,"cells":2534},"Amniotic Membrane Patch",{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2549,"PHASE4":2551,"NA":2553},{"trials":2536,"activeCount":99},[],{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[2541],{"nctId":2542,"briefTitle":2543,"status":1910,"phases":2544,"primaryCompletion":2545,"completion":2545,"start":2103,"enrollment":99,"conditions":2546,"interventions":2548},"NCT02193321","Safety and Efficacy Study of Amniotic Membrane Patch to Treat Postoperative Atrial Fibrillation",[87,88],"2015-07",[2547],"Atrial Fibrillation",[2533],{"trials":2550,"activeCount":99},[],{"trials":2552,"activeCount":99},[],{"trials":2554,"activeCount":99},[],{"intervention":2556,"totalTrials":95,"cells":2557},"anastrozole",{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2562,"PHASE3":2580,"PHASE4":2582,"NA":2584},{"trials":2559,"activeCount":99},[],{"trials":2561,"activeCount":99},[],{"trials":2563,"activeCount":99},[2564],{"nctId":2565,"briefTitle":2566,"status":299,"phases":2567,"primaryCompletion":2568,"completion":2568,"start":2569,"enrollment":290,"conditions":2570,"interventions":2578},"NCT01394211","Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer",[88],"2012-04-12","2011-07-13",[2571,2572,2573,2574,2575,2576,2577],"Estrogen Receptor-positive Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Male Breast Cancer","Recurrent Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer",[2556,2579],"pazopanib hydrochloride",{"trials":2581,"activeCount":99},[],{"trials":2583,"activeCount":99},[],{"trials":2585,"activeCount":99},[],{"intervention":2579,"totalTrials":95,"cells":2587},{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2598,"PHASE4":2600,"NA":2602},{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[2594],{"nctId":2565,"briefTitle":2566,"status":299,"phases":2595,"primaryCompletion":2568,"completion":2568,"start":2569,"enrollment":290,"conditions":2596,"interventions":2597},[88],[2571,2572,2573,2574,2575,2576,2577],[2556,2579],{"trials":2599,"activeCount":99},[],{"trials":2601,"activeCount":99},[],{"trials":2603,"activeCount":99},[],{"intervention":2605,"totalTrials":95,"cells":2606},"Broncho-Vaxom",{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2622,"PHASE4":2624,"NA":2626},{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":99},[],{"trials":2612,"activeCount":99},[2613],{"nctId":2614,"briefTitle":2615,"status":344,"phases":2616,"primaryCompletion":2617,"completion":2617,"start":2618,"enrollment":2619,"conditions":2620,"interventions":2621},"NCT02148796","Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness",[88],"2026-01-30","2017-01-01",822,[1265,1762],[2605],{"trials":2623,"activeCount":99},[],{"trials":2625,"activeCount":99},[],{"trials":2627,"activeCount":99},[],{"intervention":2629,"totalTrials":95,"cells":2630},"Vigabatrin Pill",{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2635,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2632,"activeCount":99},[],{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[2637],{"nctId":2638,"briefTitle":2639,"status":1910,"phases":2640,"primaryCompletion":2641,"completion":2641,"start":2642,"enrollment":99,"conditions":2643,"interventions":2648},"NCT04062890","Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance",[88],"2030-12-30","2030-04-15",[2644,2645,2646,2647,31],"Hyperinsulinism","Insulin Resistance","Insulin Sensitivity","Glucose Intolerance",[2629],{"trials":2650,"activeCount":99},[],{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"intervention":2096,"totalTrials":95,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":99},[2663],{"nctId":2088,"briefTitle":2089,"status":344,"phases":2664,"primaryCompletion":1337,"completion":1363,"start":2091,"enrollment":2092,"conditions":2665,"interventions":2666},[88],[2094],[2079,2096],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[],{"intervention":2674,"totalTrials":95,"cells":2675},"Injection of TVEC into target lesions - week 1-2",{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2677,"activeCount":99},[],{"trials":2679,"activeCount":99},[],{"trials":2681,"activeCount":99},[2682],{"nctId":2683,"briefTitle":2684,"status":344,"phases":2685,"primaryCompletion":2686,"completion":2686,"start":2687,"enrollment":9,"conditions":2688,"interventions":2695},"NCT03714828","Study of TVEC in Patients With Cutaneous Squamous Cell Cancer",[88],"2023-07-19","2018-12-20",[2689,2690,2691,2692,2693,2694],"Squamous Cell Carcinoma","Skin Cancer","Keratoacanthoma","Cutaneous Tumor","Skin Cancer, Squamous Cell","Lesion Skin",[2674,2696,2697,2698],"Injection of TVEC into target lesions 3wks after 1st","Injection of TVEC into target lesions 2wks after 2nd","Injection of TVEC into target lesions 2wks after 3rd",{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[],{"intervention":2696,"totalTrials":95,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2711,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2708,"activeCount":99},[],{"trials":2710,"activeCount":99},[],{"trials":2712,"activeCount":99},[2713],{"nctId":2683,"briefTitle":2684,"status":344,"phases":2714,"primaryCompletion":2686,"completion":2686,"start":2687,"enrollment":9,"conditions":2715,"interventions":2716},[88],[2689,2690,2691,2692,2693,2694],[2674,2696,2697,2698],{"trials":2718,"activeCount":99},[],{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[],{"intervention":2697,"totalTrials":95,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2729,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":99},[],{"trials":2730,"activeCount":99},[2731],{"nctId":2683,"briefTitle":2684,"status":344,"phases":2732,"primaryCompletion":2686,"completion":2686,"start":2687,"enrollment":9,"conditions":2733,"interventions":2734},[88],[2689,2690,2691,2692,2693,2694],[2674,2696,2697,2698],{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"trials":2740,"activeCount":99},[],{"intervention":2698,"totalTrials":95,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[2749],{"nctId":2683,"briefTitle":2684,"status":344,"phases":2750,"primaryCompletion":2686,"completion":2686,"start":2687,"enrollment":9,"conditions":2751,"interventions":2752},[88],[2689,2690,2691,2692,2693,2694],[2674,2696,2697,2698],{"trials":2754,"activeCount":99},[],{"trials":2756,"activeCount":99},[],{"trials":2758,"activeCount":99},[],{"intervention":2760,"totalTrials":95,"cells":2761},"Hydroxychloroquine",{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2766,"PHASE3":2781,"PHASE4":2783,"NA":2785},{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":99},[2768],{"nctId":2769,"briefTitle":2770,"status":1910,"phases":2771,"primaryCompletion":2772,"completion":2773,"start":2774,"enrollment":99,"conditions":2775,"interventions":2780},"NCT05689359","Evaluation of Hydroxychloroquine to Prevent CIPN",[88],"2025-02-01","2025-12-01","2024-06",[15,2776,2777,2778,2779],"Gynecologic Cancer","Early-stage Breast Cancer","Peripheral Neuropathy","Chemotherapy-induced Peripheral Neuropathy",[2760],{"trials":2782,"activeCount":99},[],{"trials":2784,"activeCount":99},[],{"trials":2786,"activeCount":99},[],{"intervention":2788,"totalTrials":95,"cells":2789},"Estradiol",{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[],{"trials":2795,"activeCount":99},[2796],{"nctId":2797,"briefTitle":2798,"status":344,"phases":2799,"primaryCompletion":2800,"completion":2801,"start":2802,"enrollment":2803,"conditions":2804,"interventions":2806},"NCT01923298","Estradiol Levels in Patients Treated With Estring",[88],"2018-06-30","2019-04-24","2013-08-09",14,[2805],"Estrogen Levels Among Breast Cancer Patients",[2788],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"trials":2812,"activeCount":99},[],{"intervention":2814,"totalTrials":95,"cells":2815},"Silmitasertib",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2817,"activeCount":99},[],{"trials":2819,"activeCount":99},[],{"trials":2821,"activeCount":99},[2822],{"nctId":2823,"briefTitle":2824,"status":299,"phases":2825,"primaryCompletion":2826,"completion":2827,"start":2828,"enrollment":1314,"conditions":2829,"interventions":2831},"NCT04668209","Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)",[88],"2022-06-30","2022-10-19","2021-01-21",[2830],"Coronavirus",[2814],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[],{"trials":2837,"activeCount":99},[],{"intervention":2010,"totalTrials":95,"cells":2839},{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2844,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2841,"activeCount":99},[],{"trials":2843,"activeCount":99},[],{"trials":2845,"activeCount":99},[2846],{"nctId":2002,"briefTitle":2003,"status":344,"phases":2847,"completion":2005,"start":2006,"enrollment":1162,"conditions":2848,"interventions":2849},[87,88],[919,2008],[1993,2010],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"intervention":2857,"totalTrials":95,"cells":2858},"Alpelisib",{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2863,"PHASE3":2879,"PHASE4":2881,"NA":2883},{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[2865],{"nctId":2866,"briefTitle":2867,"status":299,"phases":2868,"primaryCompletion":2869,"completion":2869,"start":2870,"enrollment":26,"conditions":2871,"interventions":2878},"NCT03601507","Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer",[88],"2022-05-24","2019-03-11",[2872,2873,2874,2875,2876,2877],"CDKN2A-p16 Positive","HPV Positive Oropharyngeal Squamous Cell Carcinoma","Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7","Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7","Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",[2857],{"trials":2880,"activeCount":99},[],{"trials":2882,"activeCount":99},[],{"trials":2884,"activeCount":99},[],{"intervention":2886,"totalTrials":95,"cells":2887},"Parenteral Nutrition",{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2889,"activeCount":99},[],{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[2894],{"nctId":2895,"briefTitle":2896,"status":299,"phases":2897,"primaryCompletion":2898,"completion":2898,"start":1477,"enrollment":2899,"conditions":2900,"interventions":2903},"NCT01937884","Supplemental Parenteral Nutrition in Pediatric Respiratory Failure",[88],"2018-08",18,[2901,2902],"Acute Respiratory Failure With Hypoxia","Malnutrition",[2886],{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[],{"trials":2909,"activeCount":99},[],{"intervention":2911,"totalTrials":95,"cells":2912},"Tamsulosin",{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2914,"activeCount":99},[],{"trials":2916,"activeCount":99},[],{"trials":2918,"activeCount":99},[2919],{"nctId":2920,"briefTitle":2921,"status":344,"phases":2922,"primaryCompletion":2923,"completion":2923,"start":2924,"enrollment":2925,"conditions":2926,"interventions":2928},"NCT04859660","Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy",[88],"2023-06-24","2021-04-16",161,[2927],"Urinary Retention Postoperative",[2911],{"trials":2930,"activeCount":99},[],{"trials":2932,"activeCount":99},[],{"trials":2934,"activeCount":99},[],{"intervention":2936,"totalTrials":95,"cells":2937},"Angiotensin 1-7",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2939,"activeCount":99},[],{"trials":2941,"activeCount":99},[],{"trials":2943,"activeCount":99},[2944],{"nctId":2945,"briefTitle":2946,"status":1286,"phases":2947,"primaryCompletion":2948,"completion":2948,"start":2949,"enrollment":2092,"conditions":2950,"interventions":2954},"NCT05336175","Biomarker Study: Heart Failure Patients at Risk",[87,88],"2023-12","2022-04",[2951,2952,2953],"Heart Failure NYHA Class II","Heart Failure NYHA Class III","Heart Failure NYHA Class IV",[2936,2955],"Saline solution",{"trials":2957,"activeCount":99},[],{"trials":2959,"activeCount":99},[],{"trials":2961,"activeCount":99},[],{"intervention":2955,"totalTrials":95,"cells":2963},{"EARLY_PHASE1":2964,"PHASE1":2966,"PHASE2":2968,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2965,"activeCount":99},[],{"trials":2967,"activeCount":99},[],{"trials":2969,"activeCount":99},[2970],{"nctId":2945,"briefTitle":2946,"status":1286,"phases":2971,"primaryCompletion":2948,"completion":2948,"start":2949,"enrollment":2092,"conditions":2972,"interventions":2973},[87,88],[2951,2952,2953],[2936,2955],{"trials":2975,"activeCount":99},[],{"trials":2977,"activeCount":99},[],{"trials":2979,"activeCount":99},[],{"intervention":2108,"totalTrials":95,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2983,"activeCount":99},[],{"trials":2985,"activeCount":99},[],{"trials":2987,"activeCount":99},[2988],{"nctId":2098,"briefTitle":2099,"status":1910,"phases":2989,"primaryCompletion":2101,"completion":2102,"start":2103,"enrollment":99,"conditions":2990,"interventions":2991},[87,88],[2105,2106],[2108,2109,2110],{"trials":2993,"activeCount":99},[],{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[],{"intervention":2109,"totalTrials":95,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[],{"trials":3005,"activeCount":99},[3006],{"nctId":2098,"briefTitle":2099,"status":1910,"phases":3007,"primaryCompletion":2101,"completion":2102,"start":2103,"enrollment":99,"conditions":3008,"interventions":3009},[87,88],[2105,2106],[2108,2109,2110],{"trials":3011,"activeCount":99},[],{"trials":3013,"activeCount":99},[],{"trials":3015,"activeCount":99},[],{"intervention":1906,"totalTrials":95,"cells":3017},{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3019,"activeCount":99},[],{"trials":3021,"activeCount":99},[],{"trials":3023,"activeCount":99},[3024],{"nctId":1895,"briefTitle":1896,"status":344,"phases":3025,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":1339,"conditions":3026,"interventions":3027},[88],[1902,1903,1904],[1906,1871],{"trials":3029,"activeCount":99},[],{"trials":3031,"activeCount":99},[],{"trials":3033,"activeCount":99},[],{"intervention":2201,"totalTrials":95,"cells":3035},{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3046,"PHASE4":3048,"NA":3050},{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[],{"trials":3041,"activeCount":99},[3042],{"nctId":2194,"briefTitle":2195,"status":344,"phases":3043,"primaryCompletion":2197,"completion":2198,"start":1289,"enrollment":1314,"conditions":3044,"interventions":3045},[88],[15],[1936,2201],{"trials":3047,"activeCount":99},[],{"trials":3049,"activeCount":99},[],{"trials":3051,"activeCount":99},[],{"intervention":1923,"totalTrials":95,"cells":3053},{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3058,"PHASE3":3064,"PHASE4":3066,"NA":3068},{"trials":3055,"activeCount":99},[],{"trials":3057,"activeCount":99},[],{"trials":3059,"activeCount":99},[3060],{"nctId":1908,"briefTitle":1909,"status":1910,"phases":3061,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":99,"conditions":3062,"interventions":3063},[88],[1915,1916,1917,1918,1919,1920,1921],[1923,1924,1925],{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[],{"intervention":3071,"totalTrials":95,"cells":3072},"Bendamustine HCL",{"EARLY_PHASE1":3073,"PHASE1":3075,"PHASE2":3077,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[],{"trials":3078,"activeCount":99},[3079],{"nctId":3080,"briefTitle":3081,"status":344,"phases":3082,"primaryCompletion":1959,"completion":3083,"start":3084,"enrollment":587,"conditions":3085,"interventions":3086},"NCT00867503","Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer",[88],"2013-04","2009-02",[1964],[3071],{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[],{"trials":3092,"activeCount":99},[],{"intervention":1935,"totalTrials":95,"cells":3094},{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3099,"PHASE3":3105,"PHASE4":3107,"NA":3109},{"trials":3096,"activeCount":99},[],{"trials":3098,"activeCount":99},[],{"trials":3100,"activeCount":99},[3101],{"nctId":1927,"briefTitle":1928,"status":344,"phases":3102,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":3103,"interventions":3104},[88],[923],[1935,1936,1937,1938,1925,1939,1940],{"trials":3106,"activeCount":99},[],{"trials":3108,"activeCount":99},[],{"trials":3110,"activeCount":99},[],{"intervention":1937,"totalTrials":95,"cells":3112},{"EARLY_PHASE1":3113,"PHASE1":3115,"PHASE2":3117,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3114,"activeCount":99},[],{"trials":3116,"activeCount":99},[],{"trials":3118,"activeCount":99},[3119],{"nctId":1927,"briefTitle":1928,"status":344,"phases":3120,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":3121,"interventions":3122},[88],[923],[1935,1936,1937,1938,1925,1939,1940],{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"trials":3128,"activeCount":99},[],{"intervention":1939,"totalTrials":95,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":99},[3137],{"nctId":1927,"briefTitle":1928,"status":344,"phases":3138,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":3139,"interventions":3140},[88],[923],[1935,1936,1937,1938,1925,1939,1940],{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[],{"trials":3146,"activeCount":99},[],{"intervention":1940,"totalTrials":95,"cells":3148},{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":99},[],{"trials":3154,"activeCount":99},[3155],{"nctId":1927,"briefTitle":1928,"status":344,"phases":3156,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":3157,"interventions":3158},[88],[923],[1935,1936,1937,1938,1925,1939,1940],{"trials":3160,"activeCount":99},[],{"trials":3162,"activeCount":99},[],{"trials":3164,"activeCount":99},[],{"intervention":3166,"totalTrials":95,"cells":3167},"Diclofenac Na gel",{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3172,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3169,"activeCount":99},[],{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":99},[3174],{"nctId":3175,"briefTitle":3176,"status":344,"phases":3177,"primaryCompletion":3178,"completion":1611,"start":3179,"enrollment":3180,"conditions":3181,"interventions":3183},"NCT00601640","Eflornithine and\u002For Diclofenac in Treating Patients With Sun-Damaged Skin",[88],"2010-02","2007-01",184,[3182],"Other Benign Neoplasm of Skin, Unspecified",[3166,3184],"Eflornithine HCL ointment",{"trials":3186,"activeCount":99},[],{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[],{"intervention":3184,"totalTrials":95,"cells":3192},{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3197,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[],{"trials":3198,"activeCount":99},[3199],{"nctId":3175,"briefTitle":3176,"status":344,"phases":3200,"primaryCompletion":3178,"completion":1611,"start":3179,"enrollment":3180,"conditions":3201,"interventions":3202},[88],[3182],[3166,3184],{"trials":3204,"activeCount":99},[],{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[],{"intervention":3210,"totalTrials":95,"cells":3211},"Omega-3 Fatty Acids",{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3216,"PHASE3":3227,"PHASE4":3229,"NA":3231},{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[],{"trials":3217,"activeCount":99},[3218],{"nctId":3219,"briefTitle":3220,"status":344,"phases":3221,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":2223,"conditions":3224,"interventions":3226},"NCT00402389","Use of Omega-3 Fatty Acids for Perinatal Depression",[88],"2006-01","2004-06",[23,3225],"Depression, Postpartum",[3210],{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[],{"intervention":3234,"totalTrials":95,"cells":3235},"Acitretin",{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3240,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3237,"activeCount":99},[],{"trials":3239,"activeCount":99},[],{"trials":3241,"activeCount":99},[3242],{"nctId":3243,"briefTitle":3244,"status":299,"phases":3245,"primaryCompletion":1611,"completion":2545,"start":1610,"enrollment":290,"conditions":3246,"interventions":3248},"NCT02050321","A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma",[88],[3247],"Malignant Melanoma",[3234,3249],"Vemurafenib",{"trials":3251,"activeCount":99},[],{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[],{"intervention":3249,"totalTrials":95,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[3264],{"nctId":3243,"briefTitle":3244,"status":299,"phases":3265,"primaryCompletion":1611,"completion":2545,"start":1610,"enrollment":290,"conditions":3266,"interventions":3267},[88],[3247],[3234,3249],{"trials":3269,"activeCount":99},[],{"trials":3271,"activeCount":99},[],{"trials":3273,"activeCount":99},[],{"intervention":3275,"totalTrials":95,"cells":3276},"0.25% Marcaine at 2ml\u002Fhr and pain medications",{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3281,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3278,"activeCount":99},[],{"trials":3280,"activeCount":99},[],{"trials":3282,"activeCount":99},[3283],{"nctId":3284,"briefTitle":3285,"status":344,"phases":3286,"primaryCompletion":3287,"completion":3287,"start":3288,"enrollment":9,"conditions":3289,"interventions":3292},"NCT03476811","Postoperative subQ Pain Control for Spinal Fusion Surgery",[88],"2021-06-30","2018-02-09",[3290,3291,187],"Spine Fusion","Surgery",[3275],{"trials":3294,"activeCount":99},[],{"trials":3296,"activeCount":99},[],{"trials":3298,"activeCount":99},[],{"intervention":3300,"totalTrials":95,"cells":3301},"Abemaciclib",{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3303,"activeCount":99},[],{"trials":3305,"activeCount":99},[],{"trials":3307,"activeCount":99},[3308],{"nctId":3309,"briefTitle":3310,"status":299,"phases":3311,"primaryCompletion":3312,"completion":3313,"start":3314,"enrollment":32,"conditions":3315,"interventions":3316},"NCT04169074","Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)",[88],"2024-12-16","2025-01-13","2021-07-07",[2371],[3300],{"trials":3318,"activeCount":99},[],{"trials":3320,"activeCount":99},[],{"trials":3322,"activeCount":99},[],{"intervention":3324,"totalTrials":95,"cells":3325},"flutamide",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3342,"PHASE4":3344,"NA":3346},{"trials":3327,"activeCount":99},[],{"trials":3329,"activeCount":99},[],{"trials":3331,"activeCount":99},[3332],{"nctId":3333,"briefTitle":3334,"status":344,"phases":3335,"primaryCompletion":3336,"completion":3337,"start":3338,"enrollment":3339,"conditions":3340,"interventions":3341},"NCT00699907","Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer",[88],"2012-11","2014-11","2005-01",127,[1964],[3324],{"trials":3343,"activeCount":99},[],{"trials":3345,"activeCount":99},[],{"trials":3347,"activeCount":99},[],{"intervention":2020,"totalTrials":95,"cells":3349},{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3351,"activeCount":99},[],{"trials":3353,"activeCount":99},[],{"trials":3355,"activeCount":99},[3356],{"nctId":2012,"briefTitle":2013,"status":344,"phases":3357,"completion":2005,"start":2015,"enrollment":688,"conditions":3358,"interventions":3359},[88],[15,2017],[1993,2019,2020,2021],{"trials":3361,"activeCount":99},[],{"trials":3363,"activeCount":99},[],{"trials":3365,"activeCount":99},[],{"intervention":2021,"totalTrials":95,"cells":3367},{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3372,"PHASE3":3378,"PHASE4":3380,"NA":3382},{"trials":3369,"activeCount":99},[],{"trials":3371,"activeCount":99},[],{"trials":3373,"activeCount":99},[3374],{"nctId":2012,"briefTitle":2013,"status":344,"phases":3375,"completion":2005,"start":2015,"enrollment":688,"conditions":3376,"interventions":3377},[88],[15,2017],[1993,2019,2020,2021],{"trials":3379,"activeCount":99},[],{"trials":3381,"activeCount":99},[],{"trials":3383,"activeCount":99},[],{"intervention":3385,"totalTrials":95,"cells":3386},"Traditional Chinese Medicine",{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3388,"activeCount":99},[],{"trials":3390,"activeCount":99},[],{"trials":3392,"activeCount":99},[3393],{"nctId":3394,"briefTitle":3395,"status":344,"phases":3396,"primaryCompletion":1337,"completion":3397,"start":3398,"enrollment":3399,"conditions":3400,"interventions":3402},"NCT00856167","Traditional Chinese Medicine (TCM) for Temporomandibular Dysfunction (TMD): A Whole Systems Multi-site Trial",[88],"2010-12","2006-10",135,[3401],"Temporomandibular Dysfunction",[3385],{"trials":3404,"activeCount":99},[],{"trials":3406,"activeCount":99},[],{"trials":3408,"activeCount":99},[],{"intervention":2279,"totalTrials":95,"cells":3410},{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3421,"PHASE4":3423,"NA":3425},{"trials":3412,"activeCount":99},[],{"trials":3414,"activeCount":99},[],{"trials":3416,"activeCount":99},[3417],{"nctId":2271,"briefTitle":2272,"status":344,"phases":3418,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":32,"conditions":3419,"interventions":3420},[88],[15,2277],[2279,2251],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[],{"intervention":3428,"totalTrials":95,"cells":3429},"Pegylated liposomal doxorubicin",{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3431,"activeCount":99},[],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[3436],{"nctId":3437,"briefTitle":3438,"status":299,"phases":3439,"primaryCompletion":3440,"completion":3440,"start":3441,"enrollment":764,"conditions":3442,"interventions":3443},"NCT01990352","Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy",[88],"2022-12-31","2013-11-05",[15],[3428],{"trials":3445,"activeCount":99},[],{"trials":3447,"activeCount":99},[],{"trials":3449,"activeCount":99},[],{"intervention":3451,"totalTrials":95,"cells":3452},"perillyl alcohol",{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[],{"trials":3458,"activeCount":99},[3459],{"nctId":3460,"briefTitle":3461,"status":344,"phases":3462,"primaryCompletion":1710,"completion":3463,"start":3464,"enrollment":3465,"conditions":3466,"interventions":3467},"NCT00608634","Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses",[88],"2009-06","2004-05",89,[1839],[3451],{"trials":3469,"activeCount":99},[],{"trials":3471,"activeCount":99},[],{"trials":3473,"activeCount":99},[],{"intervention":3475,"totalTrials":95,"cells":3476},"Pentostatin",{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3495,"PHASE4":3497,"NA":3499},{"trials":3478,"activeCount":99},[],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[3483],{"nctId":3484,"briefTitle":3485,"status":299,"phases":3486,"primaryCompletion":3487,"completion":3488,"start":3489,"enrollment":2803,"conditions":3490,"interventions":3493},"NCT00698685","Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation",[88],"2009-04-13","2011-04-26","2006-01-23",[919,923,3491,2415,2416,3492],"Hodgkin's Disease","Carcinoma, Renal Cell",[3475,3494],"Alemtuzumab",{"trials":3496,"activeCount":99},[],{"trials":3498,"activeCount":99},[],{"trials":3500,"activeCount":99},[],{"intervention":3494,"totalTrials":95,"cells":3502},{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3513,"PHASE4":3515,"NA":3517},{"trials":3504,"activeCount":99},[],{"trials":3506,"activeCount":99},[],{"trials":3508,"activeCount":99},[3509],{"nctId":3484,"briefTitle":3485,"status":299,"phases":3510,"primaryCompletion":3487,"completion":3488,"start":3489,"enrollment":2803,"conditions":3511,"interventions":3512},[88],[919,923,3491,2415,2416,3492],[3475,3494],{"trials":3514,"activeCount":99},[],{"trials":3516,"activeCount":99},[],{"trials":3518,"activeCount":99},[],{"intervention":3520,"totalTrials":95,"cells":3521},"Dexamethasone",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3523,"activeCount":99},[],{"trials":3525,"activeCount":99},[],{"trials":3527,"activeCount":99},[3528],{"nctId":3529,"briefTitle":3530,"status":299,"phases":3531,"primaryCompletion":3532,"completion":3532,"start":3533,"enrollment":3534,"conditions":3535,"interventions":3537},"NCT02410382","Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer",[88],"2018-02-16","2014-08-27",79,[617,3536],"Non-small Cell Lung Cancer",[3520],{"trials":3539,"activeCount":99},[],{"trials":3541,"activeCount":99},[],{"trials":3543,"activeCount":99},[],{"intervention":3545,"totalTrials":95,"cells":3546},"Palbociclib",{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3551,"PHASE3":3567,"PHASE4":3569,"NA":3571},{"trials":3548,"activeCount":99},[],{"trials":3550,"activeCount":99},[],{"trials":3552,"activeCount":99},[3553],{"nctId":3554,"briefTitle":3555,"status":344,"phases":3556,"primaryCompletion":3557,"completion":3557,"start":3558,"enrollment":3559,"conditions":3560,"interventions":3565},"NCT03530696","T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer",[88],"2022-12-22","2018-12-06",55,[3561,15,3562,2574,3563,3564],"HER2-positive Breast Cancer","Breast Cancer Stage","Metastatic Breast Cancer","HER2 Positive Breast Carcinoma",[3545,3566],"T-DM1",{"trials":3568,"activeCount":99},[],{"trials":3570,"activeCount":99},[],{"trials":3572,"activeCount":99},[],{"intervention":3566,"totalTrials":95,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3576,"activeCount":99},[],{"trials":3578,"activeCount":99},[],{"trials":3580,"activeCount":99},[3581],{"nctId":3554,"briefTitle":3555,"status":344,"phases":3582,"primaryCompletion":3557,"completion":3557,"start":3558,"enrollment":3559,"conditions":3583,"interventions":3584},[88],[3561,15,3562,2574,3563,3564],[3545,3566],{"trials":3586,"activeCount":99},[],{"trials":3588,"activeCount":99},[],{"trials":3590,"activeCount":99},[],{"intervention":3592,"totalTrials":95,"cells":3593},"Omacor",{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3606,"PHASE4":3608,"NA":3610},{"trials":3595,"activeCount":99},[],{"trials":3597,"activeCount":99},[],{"trials":3599,"activeCount":99},[3600],{"nctId":3601,"briefTitle":3602,"status":1910,"phases":3603,"enrollment":99,"conditions":3604,"interventions":3605},"NCT00517972","Omacor for Perimenopausal Depression",[88],[23],[3592],{"trials":3607,"activeCount":99},[],{"trials":3609,"activeCount":99},[],{"trials":3611,"activeCount":99},[],{"intervention":3613,"totalTrials":95,"cells":3614},"Chlorine Dioxide Sterilization",{"EARLY_PHASE1":3615,"PHASE1":3617,"PHASE2":3619,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3616,"activeCount":99},[],{"trials":3618,"activeCount":99},[],{"trials":3620,"activeCount":99},[3621],{"nctId":3622,"briefTitle":3623,"status":299,"phases":3624,"primaryCompletion":3625,"completion":3625,"start":3626,"enrollment":2803,"conditions":3627,"interventions":3629},"NCT03602066","Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head\u002FNeck Radiotherapy",[88],"2022-11-07","2019-02-14",[3628],"Head and Neck Carcinoma",[3613],{"trials":3631,"activeCount":99},[],{"trials":3633,"activeCount":99},[],{"trials":3635,"activeCount":99},[],{"intervention":1967,"totalTrials":290,"cells":3637},{"EARLY_PHASE1":3638,"PHASE1":3640,"PHASE2":3656,"PHASE3":3658,"PHASE4":3660,"NA":3662},{"trials":3639,"activeCount":99},[],{"trials":3641,"activeCount":99},[3642,3646],{"nctId":1956,"briefTitle":1957,"status":344,"phases":3643,"primaryCompletion":1959,"completion":1960,"start":1961,"enrollment":892,"conditions":3644,"interventions":3645},[87],[1963,1964,1965],[1948,1967,1968],{"nctId":3647,"briefTitle":3648,"status":344,"phases":3649,"primaryCompletion":2198,"completion":2545,"start":3650,"enrollment":2803,"conditions":3651,"interventions":3654},"NCT01288261","Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer",[87],"2011-01",[2572,2573,2574,3652,3653],"Stage IIIC Breast Cancer","Stage IV Breast Cancer",[1967,3655],"bavituximab",{"trials":3657,"activeCount":99},[],{"trials":3659,"activeCount":99},[],{"trials":3661,"activeCount":99},[],{"trials":3663,"activeCount":99},[],{"intervention":1968,"totalTrials":95,"cells":3665},{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3674,"PHASE3":3676,"PHASE4":3678,"NA":3680},{"trials":3667,"activeCount":99},[],{"trials":3669,"activeCount":99},[3670],{"nctId":1956,"briefTitle":1957,"status":344,"phases":3671,"primaryCompletion":1959,"completion":1960,"start":1961,"enrollment":892,"conditions":3672,"interventions":3673},[87],[1963,1964,1965],[1948,1967,1968],{"trials":3675,"activeCount":99},[],{"trials":3677,"activeCount":99},[],{"trials":3679,"activeCount":99},[],{"trials":3681,"activeCount":99},[],{"intervention":3655,"totalTrials":95,"cells":3683},{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3692,"PHASE3":3694,"PHASE4":3696,"NA":3698},{"trials":3685,"activeCount":99},[],{"trials":3687,"activeCount":99},[3688],{"nctId":3647,"briefTitle":3648,"status":344,"phases":3689,"primaryCompletion":2198,"completion":2545,"start":3650,"enrollment":2803,"conditions":3690,"interventions":3691},[87],[2572,2573,2574,3652,3653],[1967,3655],{"trials":3693,"activeCount":99},[],{"trials":3695,"activeCount":99},[],{"trials":3697,"activeCount":99},[],{"trials":3699,"activeCount":99},[],{"intervention":3701,"totalTrials":95,"cells":3702},"Taxotere",{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3718,"PHASE3":3720,"PHASE4":3722,"NA":3724},{"trials":3704,"activeCount":99},[],{"trials":3706,"activeCount":99},[3707],{"nctId":3708,"briefTitle":3709,"status":344,"phases":3710,"primaryCompletion":2103,"completion":2103,"start":3711,"enrollment":3712,"conditions":3713,"interventions":3716},"NCT01172028","Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors",[87],"2005-09",33,[15,1977,3714,617,3715,1964,25],"Gastric Cancer","Lung Cancer",[3701,3717],"Alimta",{"trials":3719,"activeCount":99},[],{"trials":3721,"activeCount":99},[],{"trials":3723,"activeCount":99},[],{"trials":3725,"activeCount":99},[],{"intervention":3717,"totalTrials":95,"cells":3727},{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3736,"PHASE3":3738,"PHASE4":3740,"NA":3742},{"trials":3729,"activeCount":99},[],{"trials":3731,"activeCount":99},[3732],{"nctId":3708,"briefTitle":3709,"status":344,"phases":3733,"primaryCompletion":2103,"completion":2103,"start":3711,"enrollment":3712,"conditions":3734,"interventions":3735},[87],[15,1977,3714,617,3715,1964,25],[3701,3717],{"trials":3737,"activeCount":99},[],{"trials":3739,"activeCount":99},[],{"trials":3741,"activeCount":99},[],{"trials":3743,"activeCount":99},[],{"intervention":3745,"totalTrials":95,"cells":3746},"Topical Myristyl Nicotinate Cream",{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3758,"PHASE3":3760,"PHASE4":3762,"NA":3764},{"trials":3748,"activeCount":99},[],{"trials":3750,"activeCount":99},[3751],{"nctId":3752,"briefTitle":3753,"status":344,"phases":3754,"primaryCompletion":3755,"completion":3755,"start":1289,"enrollment":348,"conditions":3756,"interventions":3757},"NCT00619060","Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers",[87],"2008-07",[2052],[3745],{"trials":3759,"activeCount":99},[],{"trials":3761,"activeCount":99},[],{"trials":3763,"activeCount":99},[],{"trials":3765,"activeCount":99},[],{"intervention":3767,"totalTrials":95,"cells":3768},"monoclonal antibody A27.15",{"EARLY_PHASE1":3769,"PHASE1":3771,"PHASE2":3786,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3770,"activeCount":99},[],{"trials":3772,"activeCount":99},[3773],{"nctId":3774,"briefTitle":3775,"status":344,"phases":3776,"primaryCompletion":3777,"completion":3777,"start":3778,"enrollment":3779,"conditions":3780,"interventions":3784},"NCT00003082","Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer",[87],"2001-02","1997-12",27,[3781,919,923,3782,2008,2469,3783],"Chronic Myeloproliferative Disorders","Multiple Myeloma and Plasma Cell Neoplasm","Unspecified Adult Solid Tumor, Protocol Specific",[3767,3785],"monoclonal antibody E2.3",{"trials":3787,"activeCount":99},[],{"trials":3789,"activeCount":99},[],{"trials":3791,"activeCount":99},[],{"trials":3793,"activeCount":99},[],{"intervention":3785,"totalTrials":95,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3804,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3797,"activeCount":99},[],{"trials":3799,"activeCount":99},[3800],{"nctId":3774,"briefTitle":3775,"status":344,"phases":3801,"primaryCompletion":3777,"completion":3777,"start":3778,"enrollment":3779,"conditions":3802,"interventions":3803},[87],[3781,919,923,3782,2008,2469,3783],[3767,3785],{"trials":3805,"activeCount":99},[],{"trials":3807,"activeCount":99},[],{"trials":3809,"activeCount":99},[],{"trials":3811,"activeCount":99},[],{"intervention":3813,"totalTrials":95,"cells":3814},"Sodium Bicarbonate",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3827,"PHASE3":3829,"PHASE4":3831,"NA":3833},{"trials":3816,"activeCount":99},[],{"trials":3818,"activeCount":99},[3819],{"nctId":3820,"briefTitle":3821,"status":344,"phases":3822,"primaryCompletion":3337,"completion":3823,"start":1477,"enrollment":892,"conditions":3824,"interventions":3826},"NCT02531919","Extended Use of Sodium Bicarbonate in Patients With Cancer",[87],"2015-05",[3825],"Malignant Neoplasm",[3813],{"trials":3828,"activeCount":99},[],{"trials":3830,"activeCount":99},[],{"trials":3832,"activeCount":99},[],{"trials":3834,"activeCount":99},[],{"intervention":1979,"totalTrials":95,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3845,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3838,"activeCount":99},[],{"trials":3840,"activeCount":99},[3841],{"nctId":1970,"briefTitle":1971,"status":344,"phases":3842,"primaryCompletion":1973,"completion":1974,"start":1975,"enrollment":587,"conditions":3843,"interventions":3844},[87],[1977],[1948,1979],{"trials":3846,"activeCount":99},[],{"trials":3848,"activeCount":99},[],{"trials":3850,"activeCount":99},[],{"trials":3852,"activeCount":99},[],{"intervention":3854,"totalTrials":95,"cells":3855},"Psilocybin 100 mcg\u002Fkg",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3872,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3857,"activeCount":99},[],{"trials":3859,"activeCount":99},[3860],{"nctId":3861,"briefTitle":3862,"status":344,"phases":3863,"primaryCompletion":3864,"completion":3865,"start":3866,"enrollment":892,"conditions":3867,"interventions":3869},"NCT03300947","Psilocybin for Treatment of Obsessive Compulsive Disorder",[87],"2023-10-30","2023-12-30","2019-01-02",[3868],"Obsessive-compulsive Disorder (OCD)",[3854,3870,3871],"Psilocybin 300 mcg\u002Fkg","Lorazepam 1 mg",{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[],{"trials":3877,"activeCount":99},[],{"trials":3879,"activeCount":99},[],{"intervention":3870,"totalTrials":95,"cells":3881},{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3890,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3883,"activeCount":99},[],{"trials":3885,"activeCount":99},[3886],{"nctId":3861,"briefTitle":3862,"status":344,"phases":3887,"primaryCompletion":3864,"completion":3865,"start":3866,"enrollment":892,"conditions":3888,"interventions":3889},[87],[3868],[3854,3870,3871],{"trials":3891,"activeCount":99},[],{"trials":3893,"activeCount":99},[],{"trials":3895,"activeCount":99},[],{"trials":3897,"activeCount":99},[],{"intervention":3871,"totalTrials":95,"cells":3899},{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3908,"PHASE3":3910,"PHASE4":3912,"NA":3914},{"trials":3901,"activeCount":99},[],{"trials":3903,"activeCount":99},[3904],{"nctId":3861,"briefTitle":3862,"status":344,"phases":3905,"primaryCompletion":3864,"completion":3865,"start":3866,"enrollment":892,"conditions":3906,"interventions":3907},[87],[3868],[3854,3870,3871],{"trials":3909,"activeCount":99},[],{"trials":3911,"activeCount":99},[],{"trials":3913,"activeCount":99},[],{"trials":3915,"activeCount":99},[],{"intervention":3917,"totalTrials":95,"cells":3918},"Meriva",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3920,"activeCount":99},[],{"trials":3922,"activeCount":99},[3923],{"nctId":3924,"briefTitle":3925,"status":299,"phases":3926,"primaryCompletion":3927,"completion":3928,"start":3929,"enrollment":1949,"conditions":3930,"interventions":3932},"NCT02543931","Curcuma Longa L in Rheumatoid Arthritis",[87],"2017-06","2017-09","2015-11",[3931],"Rheumatoid Arthritis",[3917],{"trials":3934,"activeCount":99},[],{"trials":3936,"activeCount":99},[],{"trials":3938,"activeCount":99},[],{"trials":3940,"activeCount":99},[],{"intervention":3942,"totalTrials":95,"cells":3943},"Intervention: Ketamine",{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3959,"PHASE3":3961,"PHASE4":3963,"NA":3965},{"trials":3945,"activeCount":99},[],{"trials":3947,"activeCount":99},[3948],{"nctId":3949,"briefTitle":3950,"status":1286,"phases":3951,"primaryCompletion":3952,"completion":3953,"start":3954,"enrollment":26,"conditions":3955,"interventions":3958},"NCT06021756","Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease",[87],"2022-08-25","2023-08-25","2019-07-28",[3956,3957],"Levodopa-Induced Dyskinesia","Parkinson's Disease",[3942],{"trials":3960,"activeCount":99},[],{"trials":3962,"activeCount":99},[],{"trials":3964,"activeCount":99},[],{"trials":3966,"activeCount":99},[],{"intervention":3968,"totalTrials":95,"cells":3969},"Rucaparib",{"EARLY_PHASE1":3970,"PHASE1":3980,"PHASE2":3982,"PHASE3":3984,"PHASE4":3986,"NA":3988},{"trials":3971,"activeCount":99},[3972],{"nctId":3973,"briefTitle":3974,"status":344,"phases":3975,"primaryCompletion":3976,"completion":3976,"start":3977,"enrollment":261,"conditions":3978,"interventions":3979},"NCT03911453","Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",[86],"2021-07-16","2019-04-19",[15],[3968],{"trials":3981,"activeCount":99},[],{"trials":3983,"activeCount":99},[],{"trials":3985,"activeCount":99},[],{"trials":3987,"activeCount":99},[],{"trials":3989,"activeCount":99},[],{"intervention":3991,"totalTrials":95,"cells":3992},"Administration of albuterol",{"EARLY_PHASE1":3993,"PHASE1":4004,"PHASE2":4006,"PHASE3":4008,"PHASE4":4010,"NA":4012},{"trials":3994,"activeCount":99},[3995],{"nctId":3996,"briefTitle":3997,"status":1910,"phases":3998,"primaryCompletion":3999,"completion":3999,"start":4000,"enrollment":99,"conditions":4001,"interventions":4003},"NCT03889379","Albuterol and Immune Cell Composition",[86],"2021-06-20","2019-01-20",[4002],"Immune Cell Composition",[3991],{"trials":4005,"activeCount":99},[],{"trials":4007,"activeCount":99},[],{"trials":4009,"activeCount":99},[],{"trials":4011,"activeCount":99},[],{"trials":4013,"activeCount":99},[],{"intervention":4015,"totalTrials":95,"cells":4016},"SARS-COV2 Pfizer Vaccine",{"EARLY_PHASE1":4017,"PHASE1":4031,"PHASE2":4033,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4018,"activeCount":99},[4019],{"nctId":4020,"briefTitle":4021,"status":344,"phases":4022,"primaryCompletion":4023,"completion":4024,"start":4025,"enrollment":261,"conditions":4026,"interventions":4030},"NCT04936997","Immune Response to the COVID-19 Vaccine",[86],"2021-08-25","2022-05-08","2021-06-07",[4027,21,4028,4029],"Covid19","Malignancy","Vaccine Response Impaired",[4015],{"trials":4032,"activeCount":99},[],{"trials":4034,"activeCount":99},[],{"trials":4036,"activeCount":99},[],{"trials":4038,"activeCount":99},[],{"trials":4040,"activeCount":99},[],{"intervention":4042,"totalTrials":95,"cells":4043},"Avmacol®",{"EARLY_PHASE1":4044,"PHASE1":4061,"PHASE2":4063,"PHASE3":4065,"PHASE4":4067,"NA":4069},{"trials":4045,"activeCount":99},[4046],{"nctId":4047,"briefTitle":4048,"status":344,"phases":4049,"primaryCompletion":4050,"completion":4051,"start":4052,"enrollment":303,"conditions":4053,"interventions":4060},"NCT03182959","Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer",[86],"2020-01-01","2021-01-19","2017-04-24",[2371,617,4054,4055,4056,4057,4058,4059],"Head and Neck Squamous Cell Carcinoma","Tobacco-Related Carcinoma","Carcinoma in Situ","Dysplasia","Hyperplasia","Premalignant Lesion",[4042],{"trials":4062,"activeCount":99},[],{"trials":4064,"activeCount":99},[],{"trials":4066,"activeCount":99},[],{"trials":4068,"activeCount":99},[],{"trials":4070,"activeCount":99},[],{"intervention":4072,"totalTrials":95,"cells":4073},"Acetazolamide",{"EARLY_PHASE1":4074,"PHASE1":4085,"PHASE2":4087,"PHASE3":4089,"PHASE4":4091,"NA":4093},{"trials":4075,"activeCount":99},[4076],{"nctId":4077,"briefTitle":4078,"status":1286,"phases":4079,"primaryCompletion":4080,"completion":4080,"start":4081,"enrollment":4082,"conditions":4083,"interventions":4084},"NCT06110078","Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption",[86],"2024-05-01","2024-01-18",44,[18],[4072],{"trials":4086,"activeCount":99},[],{"trials":4088,"activeCount":99},[],{"trials":4090,"activeCount":99},[],{"trials":4092,"activeCount":99},[],{"trials":4094,"activeCount":99},[],{"intervention":2265,"totalTrials":95,"cells":4096},{"EARLY_PHASE1":4097,"PHASE1":4103,"PHASE2":4105,"PHASE3":4107,"PHASE4":4109,"NA":4111},{"trials":4098,"activeCount":99},[4099],{"nctId":2256,"briefTitle":2257,"status":344,"phases":4100,"primaryCompletion":2259,"completion":2260,"start":2261,"enrollment":2223,"conditions":4101,"interventions":4102},[86],[2263],[2251,2265],{"trials":4104,"activeCount":99},[],{"trials":4106,"activeCount":99},[],{"trials":4108,"activeCount":99},[],{"trials":4110,"activeCount":99},[],{"trials":4112,"activeCount":99},[],{"intervention":4114,"totalTrials":95,"cells":4115},"Nitrous oxide",{"EARLY_PHASE1":4116,"PHASE1":4128,"PHASE2":4130,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4117,"activeCount":99},[4118],{"nctId":4119,"briefTitle":4120,"status":299,"phases":4121,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":1949,"conditions":4124,"interventions":4126},"NCT06661005","Nitrous Oxide for Pain Management During In-Office Gynecology Procedures",[86],"2021-09-01","2021-05-17",[4125],"Nitrous Oxide",[4114,4127],"IV Sedation",{"trials":4129,"activeCount":99},[],{"trials":4131,"activeCount":99},[],{"trials":4133,"activeCount":99},[],{"trials":4135,"activeCount":99},[],{"trials":4137,"activeCount":99},[],{"intervention":4127,"totalTrials":95,"cells":4139},{"EARLY_PHASE1":4140,"PHASE1":4146,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4141,"activeCount":99},[4142],{"nctId":4119,"briefTitle":4120,"status":299,"phases":4143,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":1949,"conditions":4144,"interventions":4145},[86],[4125],[4114,4127],{"trials":4147,"activeCount":99},[],{"trials":4149,"activeCount":99},[],{"trials":4151,"activeCount":99},[],{"trials":4153,"activeCount":99},[],{"trials":4155,"activeCount":99},[],{"intervention":4157,"totalTrials":95,"cells":4158},"Syndros",{"EARLY_PHASE1":4159,"PHASE1":4171,"PHASE2":4173,"PHASE3":4175,"PHASE4":4177,"NA":4179},{"trials":4160,"activeCount":99},[4161],{"nctId":4162,"briefTitle":4163,"status":344,"phases":4164,"primaryCompletion":4165,"completion":4166,"start":4167,"enrollment":2803,"conditions":4168,"interventions":4170},"NCT03661892","Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets",[86],"2020-10-30","2021-04-26","2018-12-19",[4169,15,1431],"Bone Metastases",[4157],{"trials":4172,"activeCount":99},[],{"trials":4174,"activeCount":99},[],{"trials":4176,"activeCount":99},[],{"trials":4178,"activeCount":99},[],{"trials":4180,"activeCount":99},[],{"intervention":4182,"totalTrials":95,"cells":4183},"Fomepizole",{"EARLY_PHASE1":4184,"PHASE1":4196,"PHASE2":4198,"PHASE3":4200,"PHASE4":4202,"NA":4204},{"trials":4185,"activeCount":99},[4186],{"nctId":4187,"briefTitle":4188,"status":344,"phases":4189,"primaryCompletion":4190,"completion":4190,"start":4191,"enrollment":303,"conditions":4192,"interventions":4194},"NCT03878693","4-methylpyrazole and Acetaminophen Metabolism",[86],"2018-10-31","2018-07-01",[4193],"Healthy Adult Volunteers",[4182,4195],"APAP",{"trials":4197,"activeCount":99},[],{"trials":4199,"activeCount":99},[],{"trials":4201,"activeCount":99},[],{"trials":4203,"activeCount":99},[],{"trials":4205,"activeCount":99},[],{"intervention":4195,"totalTrials":95,"cells":4207},{"EARLY_PHASE1":4208,"PHASE1":4214,"PHASE2":4216,"PHASE3":4218,"PHASE4":4220,"NA":4222},{"trials":4209,"activeCount":99},[4210],{"nctId":4187,"briefTitle":4188,"status":344,"phases":4211,"primaryCompletion":4190,"completion":4190,"start":4191,"enrollment":303,"conditions":4212,"interventions":4213},[86],[4193],[4182,4195],{"trials":4215,"activeCount":99},[],{"trials":4217,"activeCount":99},[],{"trials":4219,"activeCount":99},[],{"trials":4221,"activeCount":99},[],{"trials":4223,"activeCount":99},[],{"intervention":4225,"totalTrials":95,"cells":4226},"Keratinocyte growth factor",{"EARLY_PHASE1":4227,"PHASE1":4241,"PHASE2":4243,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4228,"activeCount":99},[4229],{"nctId":4230,"briefTitle":4231,"status":344,"phases":4232,"primaryCompletion":4233,"completion":4233,"start":4234,"enrollment":1932,"conditions":4235,"interventions":4240},"NCT04554732","Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia",[86],"2022-06-24","2020-04-27",[4236,4237,4238,4239],"Alopecia","Chemotherapy-Induced Change","Hair Loss","Alopecia Drugs",[4225],{"trials":4242,"activeCount":99},[],{"trials":4244,"activeCount":99},[],{"trials":4246,"activeCount":99},[],{"trials":4248,"activeCount":99},[],{"trials":4250,"activeCount":99},[],{"intervention":4252,"totalTrials":95,"cells":4253},"Everolimus",{"EARLY_PHASE1":4254,"PHASE1":4266,"PHASE2":4268,"PHASE3":4270,"PHASE4":4272,"NA":4274},{"trials":4255,"activeCount":99},[4256],{"nctId":4257,"briefTitle":4258,"status":299,"phases":4259,"primaryCompletion":4260,"completion":4260,"start":4261,"enrollment":290,"conditions":4262,"interventions":4265},"NCT03578432","Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy",[86],"2019-11-15","2018-05-04",[4263,4264,617],"Salivary Gland Dysfunction","Xerostomia",[4252],{"trials":4267,"activeCount":99},[],{"trials":4269,"activeCount":99},[],{"trials":4271,"activeCount":99},[],{"trials":4273,"activeCount":99},[],{"trials":4275,"activeCount":99},[],{"intervention":4277,"totalTrials":95,"cells":4278},"Ketamine Hcl 100Mg\u002FMl Inj",{"EARLY_PHASE1":4279,"PHASE1":4291,"PHASE2":4293,"PHASE3":4295,"PHASE4":4297,"NA":4299},{"trials":4280,"activeCount":99},[4281],{"nctId":4282,"briefTitle":4283,"status":299,"phases":4284,"primaryCompletion":4285,"completion":4285,"start":4286,"enrollment":587,"conditions":4287,"interventions":4290},"NCT03067974","Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study",[86],"2019-01-22","2017-09-21",[4288,4289],"Failed Moderate Sedation During Procedure","Ketamine Adverse Reaction",[4277],{"trials":4292,"activeCount":99},[],{"trials":4294,"activeCount":99},[],{"trials":4296,"activeCount":99},[],{"trials":4298,"activeCount":99},[],{"trials":4300,"activeCount":99},[],{"intervention":4302,"totalTrials":290,"cells":4303},"Misoprostol",{"EARLY_PHASE1":4304,"PHASE1":4306,"PHASE2":4308,"PHASE3":4318,"PHASE4":4320,"NA":4322},{"trials":4305,"activeCount":99},[],{"trials":4307,"activeCount":99},[],{"trials":4309,"activeCount":99},[4310],{"nctId":4311,"briefTitle":4312,"status":1286,"phases":4313,"primaryCompletion":4314,"completion":4314,"start":3083,"enrollment":115,"conditions":4315,"interventions":4317},"NCT01866488","The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor",[88],"2016-10",[4316],"Labor Induction",[4302],{"trials":4319,"activeCount":99},[],{"trials":4321,"activeCount":99},[],{"trials":4323,"activeCount":99},[4324],{"nctId":4325,"briefTitle":4326,"status":344,"phases":4327,"primaryCompletion":3650,"completion":4328,"start":4329,"enrollment":4330,"conditions":4331,"interventions":4333},"NCT01001897","Use of Misoprostol for Intrauterine Device (IUD) Insertion in Nulliparous Women",[91],"2011-04","2009-10",61,[4332],"Contraception",[4302],{"intervention":4335,"totalTrials":95,"cells":4336},"therapeutic estradiol",{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4343,"PHASE4":4345,"NA":4347},{"trials":4338,"activeCount":99},[],{"trials":4340,"activeCount":99},[],{"trials":4342,"activeCount":99},[],{"trials":4344,"activeCount":99},[],{"trials":4346,"activeCount":99},[],{"trials":4348,"activeCount":99},[4349],{"nctId":4350,"briefTitle":4351,"status":344,"phases":4352,"primaryCompletion":4353,"completion":4354,"start":4355,"enrollment":1263,"conditions":4356,"interventions":4358},"NCT01385280","Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer",[91],"2013-01","2013-10","2011-02",[2571,4357,2574,3652,3653],"Progesterone Receptor Positive Tumor",[4335,4359],"exemestane",{"intervention":4359,"totalTrials":95,"cells":4361},{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4368,"PHASE4":4370,"NA":4372},{"trials":4363,"activeCount":99},[],{"trials":4365,"activeCount":99},[],{"trials":4367,"activeCount":99},[],{"trials":4369,"activeCount":99},[],{"trials":4371,"activeCount":99},[],{"trials":4373,"activeCount":99},[4374],{"nctId":4350,"briefTitle":4351,"status":344,"phases":4375,"primaryCompletion":4353,"completion":4354,"start":4355,"enrollment":1263,"conditions":4376,"interventions":4377},[91],[2571,4357,2574,3652,3653],[4335,4359],{"intervention":4379,"totalTrials":95,"cells":4380},"Oneome RightMEd Pharmacogenomic testing Kit",{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4387,"PHASE4":4389,"NA":4391},{"trials":4382,"activeCount":99},[],{"trials":4384,"activeCount":99},[],{"trials":4386,"activeCount":99},[],{"trials":4388,"activeCount":99},[],{"trials":4390,"activeCount":99},[],{"trials":4392,"activeCount":99},[4393],{"nctId":4394,"briefTitle":4395,"status":1286,"phases":4396,"primaryCompletion":4397,"completion":4398,"start":4399,"enrollment":4400,"conditions":4401,"interventions":4403},"NCT04909749","CDDOM Oneome Rightmed Depression Study",[91],"2022-06","2023-06","2021-06",350,[4402],"Depression, Anxiety",[4379],{"intervention":4405,"totalTrials":95,"cells":4406},"fenretinide",{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4411,"PHASE3":4413,"PHASE4":4415,"NA":4417},{"trials":4408,"activeCount":99},[],{"trials":4410,"activeCount":99},[],{"trials":4412,"activeCount":99},[],{"trials":4414,"activeCount":99},[],{"trials":4416,"activeCount":99},[],{"trials":4418,"activeCount":99},[4419],{"nctId":4420,"briefTitle":4421,"status":344,"phases":4422,"primaryCompletion":4423,"completion":4424,"start":4425,"enrollment":2092,"conditions":4426,"interventions":4429},"NCT00098800","Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries",[91],"2006-08","2006-11","2004-10",[4427,4428,1964],"brca1 Mutation Carrier","brca2 Mutation Carrier",[4405],{"intervention":4431,"totalTrials":95,"cells":4432},"Metformin Hydrochloride",{"EARLY_PHASE1":4433,"PHASE1":4435,"PHASE2":4437,"PHASE3":4439,"PHASE4":4441,"NA":4443},{"trials":4434,"activeCount":99},[],{"trials":4436,"activeCount":99},[],{"trials":4438,"activeCount":99},[],{"trials":4440,"activeCount":99},[],{"trials":4442,"activeCount":99},[],{"trials":4444,"activeCount":99},[4445],{"nctId":4446,"briefTitle":4447,"status":1286,"phases":4448,"primaryCompletion":4449,"completion":4449,"start":1974,"enrollment":4450,"conditions":4451,"interventions":4453},"NCT02548741","Evaluation of the Metformin Effect on Methylglyoxal in Patients With Type 2 Diabetes",[91],"2017-08",120,[4452],"Type 2 Diabetes Mellitus",[4431,4454],"Calcium carbonate",{"intervention":4454,"totalTrials":95,"cells":4456},{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4463,"PHASE4":4465,"NA":4467},{"trials":4458,"activeCount":99},[],{"trials":4460,"activeCount":99},[],{"trials":4462,"activeCount":99},[],{"trials":4464,"activeCount":99},[],{"trials":4466,"activeCount":99},[],{"trials":4468,"activeCount":99},[4469],{"nctId":4446,"briefTitle":4447,"status":1286,"phases":4470,"primaryCompletion":4449,"completion":4449,"start":1974,"enrollment":4450,"conditions":4471,"interventions":4472},[91],[4452],[4431,4454],{"intervention":4474,"totalTrials":95,"cells":4475},"DNA analysis",{"EARLY_PHASE1":4476,"PHASE1":4478,"PHASE2":4480,"PHASE3":4482,"PHASE4":4484,"NA":4486},{"trials":4477,"activeCount":99},[],{"trials":4479,"activeCount":99},[],{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[],{"trials":4485,"activeCount":99},[],{"trials":4487,"activeCount":99},[4488],{"nctId":4489,"briefTitle":4490,"status":344,"phases":4491,"primaryCompletion":2049,"completion":2049,"start":4492,"enrollment":3779,"conditions":4493,"interventions":4495},"NCT00900341","Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma",[],"2005-08",[4494],"Sarcoma",[4474,4496,4497,4498,4499],"gene expression analysis","protein expression analysis","reverse transcriptase-polymerase chain reaction","western blotting",{"intervention":4496,"totalTrials":95,"cells":4501},{"EARLY_PHASE1":4502,"PHASE1":4504,"PHASE2":4506,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4503,"activeCount":99},[],{"trials":4505,"activeCount":99},[],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[],{"trials":4513,"activeCount":99},[4514],{"nctId":4489,"briefTitle":4490,"status":344,"phases":4515,"primaryCompletion":2049,"completion":2049,"start":4492,"enrollment":3779,"conditions":4516,"interventions":4517},[],[4494],[4474,4496,4497,4498,4499],{"intervention":4497,"totalTrials":95,"cells":4519},{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4521,"activeCount":99},[],{"trials":4523,"activeCount":99},[],{"trials":4525,"activeCount":99},[],{"trials":4527,"activeCount":99},[],{"trials":4529,"activeCount":99},[],{"trials":4531,"activeCount":99},[4532],{"nctId":4489,"briefTitle":4490,"status":344,"phases":4533,"primaryCompletion":2049,"completion":2049,"start":4492,"enrollment":3779,"conditions":4534,"interventions":4535},[],[4494],[4474,4496,4497,4498,4499],{"intervention":4498,"totalTrials":95,"cells":4537},{"EARLY_PHASE1":4538,"PHASE1":4540,"PHASE2":4542,"PHASE3":4544,"PHASE4":4546,"NA":4548},{"trials":4539,"activeCount":99},[],{"trials":4541,"activeCount":99},[],{"trials":4543,"activeCount":99},[],{"trials":4545,"activeCount":99},[],{"trials":4547,"activeCount":99},[],{"trials":4549,"activeCount":99},[4550],{"nctId":4489,"briefTitle":4490,"status":344,"phases":4551,"primaryCompletion":2049,"completion":2049,"start":4492,"enrollment":3779,"conditions":4552,"interventions":4553},[],[4494],[4474,4496,4497,4498,4499],{"intervention":4499,"totalTrials":95,"cells":4555},{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4560,"PHASE3":4562,"PHASE4":4564,"NA":4566},{"trials":4557,"activeCount":99},[],{"trials":4559,"activeCount":99},[],{"trials":4561,"activeCount":99},[],{"trials":4563,"activeCount":99},[],{"trials":4565,"activeCount":99},[],{"trials":4567,"activeCount":99},[4568],{"nctId":4489,"briefTitle":4490,"status":344,"phases":4569,"primaryCompletion":2049,"completion":2049,"start":4492,"enrollment":3779,"conditions":4570,"interventions":4571},[],[4494],[4474,4496,4497,4498,4499],{"intervention":4573,"totalTrials":95,"cells":4574},"Interferon-alpha",{"EARLY_PHASE1":4575,"PHASE1":4577,"PHASE2":4579,"PHASE3":4581,"PHASE4":4583,"NA":4585},{"trials":4576,"activeCount":99},[],{"trials":4578,"activeCount":99},[],{"trials":4580,"activeCount":99},[],{"trials":4582,"activeCount":99},[],{"trials":4584,"activeCount":99},[],{"trials":4586,"activeCount":99},[4587],{"nctId":4588,"briefTitle":4589,"status":1910,"phases":4590,"primaryCompletion":4591,"completion":4591,"start":4592,"enrollment":99,"conditions":4593,"interventions":4595},"NCT01625793","Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes",[91],"2013-07","2012-06",[4594],"Hepatitis C",[4573],{"intervention":4597,"totalTrials":95,"cells":4598},"oral dexamethasone",{"EARLY_PHASE1":4599,"PHASE1":4601,"PHASE2":4603,"PHASE3":4605,"PHASE4":4607,"NA":4609},{"trials":4600,"activeCount":99},[],{"trials":4602,"activeCount":99},[],{"trials":4604,"activeCount":99},[],{"trials":4606,"activeCount":99},[],{"trials":4608,"activeCount":99},[],{"trials":4610,"activeCount":99},[4611],{"nctId":4612,"briefTitle":4613,"status":344,"phases":4614,"primaryCompletion":4615,"completion":4615,"start":4616,"enrollment":4617,"conditions":4618,"interventions":4621},"NCT03005522","The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess",[91],"2019-12","2017-01",73,[4619,4620],"Dental Research","Pharmaceutical Preparations, Dental",[4597],{"intervention":4623,"totalTrials":95,"cells":4624},"150 mcg levonorgestrel\u002F30 mcg ethinyl estradiol",{"EARLY_PHASE1":4625,"PHASE1":4627,"PHASE2":4629,"PHASE3":4631,"PHASE4":4633,"NA":4635},{"trials":4626,"activeCount":99},[],{"trials":4628,"activeCount":99},[],{"trials":4630,"activeCount":99},[],{"trials":4632,"activeCount":99},[],{"trials":4634,"activeCount":99},[],{"trials":4636,"activeCount":99},[4637],{"nctId":4638,"briefTitle":4639,"status":1286,"phases":4640,"primaryCompletion":4641,"completion":4642,"start":4643,"enrollment":4644,"conditions":4645,"interventions":4646},"NCT05116371","Control of Bleeding on Nexplanon in Latinx Patients",[],"2023-12-01","2024-12-01","2021-12-01",144,[4332],[4623],{"intervention":4648,"totalTrials":95,"cells":4649},"Ketamine",{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4651,"activeCount":99},[],{"trials":4653,"activeCount":99},[],{"trials":4655,"activeCount":99},[],{"trials":4657,"activeCount":99},[],{"trials":4659,"activeCount":99},[],{"trials":4661,"activeCount":99},[4662],{"nctId":4663,"briefTitle":4664,"status":299,"phases":4665,"primaryCompletion":4666,"completion":4666,"start":4667,"enrollment":1208,"conditions":4668,"interventions":4670},"NCT01900847","Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department",[91],"2014-04-01","2013-06-01",[4669],"Acute Pain",[4648,4671],"Morphine",{"intervention":4671,"totalTrials":95,"cells":4673},{"EARLY_PHASE1":4674,"PHASE1":4676,"PHASE2":4678,"PHASE3":4680,"PHASE4":4682,"NA":4684},{"trials":4675,"activeCount":99},[],{"trials":4677,"activeCount":99},[],{"trials":4679,"activeCount":99},[],{"trials":4681,"activeCount":99},[],{"trials":4683,"activeCount":99},[],{"trials":4685,"activeCount":99},[4686],{"nctId":4663,"briefTitle":4664,"status":299,"phases":4687,"primaryCompletion":4666,"completion":4666,"start":4667,"enrollment":1208,"conditions":4688,"interventions":4689},[91],[4669],[4648,4671],{"intervention":4691,"totalTrials":95,"cells":4692},"Influenza Vaccination",{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4697,"PHASE3":4699,"PHASE4":4701,"NA":4703},{"trials":4694,"activeCount":99},[],{"trials":4696,"activeCount":99},[],{"trials":4698,"activeCount":99},[],{"trials":4700,"activeCount":99},[],{"trials":4702,"activeCount":99},[],{"trials":4704,"activeCount":99},[4705],{"nctId":4706,"briefTitle":4707,"status":344,"phases":4708,"primaryCompletion":4709,"completion":4709,"start":4710,"enrollment":1664,"conditions":4711,"interventions":4712},"NCT00822627","Influenza Vaccination in the Emergency Department",[91],"2008-04","2007-11",[1165],[4691],{"intervention":4714,"totalTrials":95,"cells":4715},"Systemic anticoagulation",{"EARLY_PHASE1":4716,"PHASE1":4718,"PHASE2":4720,"PHASE3":4722,"PHASE4":4724,"NA":4726},{"trials":4717,"activeCount":99},[],{"trials":4719,"activeCount":99},[],{"trials":4721,"activeCount":99},[],{"trials":4723,"activeCount":99},[],{"trials":4725,"activeCount":99},[],{"trials":4727,"activeCount":99},[4728],{"nctId":4729,"briefTitle":4730,"status":1286,"phases":4731,"primaryCompletion":4641,"completion":4732,"start":1807,"enrollment":2223,"conditions":4733,"interventions":4737},"NCT05133713","Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone",[],"2024-01-01",[4734,4735,4736],"Pulmonary Embolism","Pulmonary Hypertension","Chronic Thromboembolic Pulmonary Hypertension",[4714],{"intervention":4739,"totalTrials":95,"cells":4740},"Albuterol",{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4747,"PHASE4":4749,"NA":4751},{"trials":4742,"activeCount":99},[],{"trials":4744,"activeCount":99},[],{"trials":4746,"activeCount":99},[],{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[],{"trials":4752,"activeCount":99},[4753],{"nctId":4754,"briefTitle":4755,"status":344,"phases":4756,"primaryCompletion":2050,"completion":4353,"start":4757,"enrollment":1478,"conditions":4758,"interventions":4760},"NCT01880723","Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis",[91],"2009-05",[4759,2052],"Cystic Fibrosis",[4739],{"intervention":4762,"totalTrials":95,"cells":4763},"Interferon alpha",{"EARLY_PHASE1":4764,"PHASE1":4766,"PHASE2":4768,"PHASE3":4770,"PHASE4":4772,"NA":4774},{"trials":4765,"activeCount":99},[],{"trials":4767,"activeCount":99},[],{"trials":4769,"activeCount":99},[],{"trials":4771,"activeCount":99},[],{"trials":4773,"activeCount":99},[],{"trials":4775,"activeCount":99},[4776],{"nctId":4777,"briefTitle":4778,"status":344,"phases":4779,"primaryCompletion":1363,"completion":1363,"start":3755,"enrollment":338,"conditions":4780,"interventions":4781},"NCT02074605","Cognitive Effects of Interferon in Patients With Melanoma",[],[738],[4762],{"intervention":4783,"totalTrials":95,"cells":4784},"NRT Patch",{"EARLY_PHASE1":4785,"PHASE1":4787,"PHASE2":4789,"PHASE3":4791,"PHASE4":4793,"NA":4795},{"trials":4786,"activeCount":99},[],{"trials":4788,"activeCount":99},[],{"trials":4790,"activeCount":99},[],{"trials":4792,"activeCount":99},[],{"trials":4794,"activeCount":99},[],{"trials":4796,"activeCount":99},[4797],{"nctId":4798,"briefTitle":4799,"status":344,"phases":4800,"primaryCompletion":4801,"completion":4802,"start":4803,"enrollment":4804,"conditions":4805,"interventions":4807},"NCT03908320","Menstrual Phase and Smoking Cessation at a State Quitline",[91],"2020-05-31","2020-09-30","2019-01-15",119,[4806],"Menstrual Cycle",[4783],{"intervention":4809,"totalTrials":95,"cells":4810},"HEP-IV",{"EARLY_PHASE1":4811,"PHASE1":4813,"PHASE2":4815,"PHASE3":4817,"PHASE4":4819,"NA":4821},{"trials":4812,"activeCount":99},[],{"trials":4814,"activeCount":99},[],{"trials":4816,"activeCount":99},[],{"trials":4818,"activeCount":99},[],{"trials":4820,"activeCount":99},[],{"trials":4822,"activeCount":99},[4823],{"nctId":4824,"briefTitle":4825,"status":1910,"phases":4826,"primaryCompletion":4827,"completion":4828,"start":4829,"enrollment":99,"conditions":4830,"interventions":4834},"NCT02966080","Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.",[91],"2020-12","2021-02","2016-12",[4831,4832,4833],"Acute Respiratory Failure","Extracorporeal Membrane Oxygenation Complication","Bleeding",[4809],{"intervention":4836,"totalTrials":95,"cells":4837},"Personal genomic educational testing",{"EARLY_PHASE1":4838,"PHASE1":4840,"PHASE2":4842,"PHASE3":4844,"PHASE4":4846,"NA":4848},{"trials":4839,"activeCount":99},[],{"trials":4841,"activeCount":99},[],{"trials":4843,"activeCount":99},[],{"trials":4845,"activeCount":99},[],{"trials":4847,"activeCount":99},[],{"trials":4849,"activeCount":99},[4850],{"nctId":4851,"briefTitle":4852,"status":344,"phases":4853,"primaryCompletion":4854,"completion":4854,"start":4855,"enrollment":4856,"conditions":4857,"interventions":4858},"NCT04889014","Efficacy of Personal Pharmacogenomic Testing as an Educational Tool in the Pharmacy Curriculum",[91],"2021-03-01","2016-03-03",233,[2052],[4836,4859],"No personal genomic educational testing",{"intervention":4859,"totalTrials":95,"cells":4861},{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4866,"PHASE3":4868,"PHASE4":4870,"NA":4872},{"trials":4863,"activeCount":99},[],{"trials":4865,"activeCount":99},[],{"trials":4867,"activeCount":99},[],{"trials":4869,"activeCount":99},[],{"trials":4871,"activeCount":99},[],{"trials":4873,"activeCount":99},[4874],{"nctId":4851,"briefTitle":4852,"status":344,"phases":4875,"primaryCompletion":4854,"completion":4854,"start":4855,"enrollment":4856,"conditions":4876,"interventions":4877},[91],[2052],[4836,4859],{"intervention":4879,"totalTrials":95,"cells":4880},"Aprepitant",{"EARLY_PHASE1":4881,"PHASE1":4883,"PHASE2":4885,"PHASE3":4887,"PHASE4":4889,"NA":4891},{"trials":4882,"activeCount":99},[],{"trials":4884,"activeCount":99},[],{"trials":4886,"activeCount":99},[],{"trials":4888,"activeCount":99},[],{"trials":4890,"activeCount":99},[],{"trials":4892,"activeCount":99},[4893],{"nctId":4894,"briefTitle":4895,"status":1286,"phases":4896,"primaryCompletion":4314,"start":4897,"enrollment":2223,"conditions":4898,"interventions":4900},"NCT02226601","Aprepitant to Mitigate Opioids' Cognitive Side Effects",[91],"2014-10",[4899],"Cognitive Dysfunction",[4879],{"intervention":4902,"totalTrials":95,"cells":4903},"Syntocinon",{"EARLY_PHASE1":4904,"PHASE1":4906,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4914},{"trials":4905,"activeCount":99},[],{"trials":4907,"activeCount":99},[],{"trials":4909,"activeCount":99},[],{"trials":4911,"activeCount":99},[],{"trials":4913,"activeCount":99},[],{"trials":4915,"activeCount":99},[4916],{"nctId":4917,"briefTitle":4918,"status":344,"phases":4919,"primaryCompletion":4920,"completion":4920,"start":4921,"enrollment":4082,"conditions":4922,"interventions":4925},"NCT04505904","Oxytocin and Approach-avoid in Grief",[91],"2017-05-12","2015-03-20",[4923,4924],"Prolonged Grief Disorder","Bereavement",[4902]]